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   This	  thesis	  reports	  on	  a	  method	  to	  improve	  in	  vitro	  diagnostic	  assays	  that	  detect	  
immune	  response,	  with	  specific	  application	  to	  HIV-­‐1.	  	  The	  inherent	  polyclonal	  diversity	  of	  
the	  humoral	  immune	  response	  was	  addressed	  by	  using	  sequential	  in	  situ	  click	  chemistry	  
to	  develop	  a	  cocktail	  of	  peptide-­‐based	  capture	  agents,	  the	  components	  of	  which	  were	  
raised	  against	  different,	  representative	  anti-­‐HIV	  antibodies	  that	  bind	  to	  a	  conserved	  
epitope	  of	  the	  HIV-­‐1	  envelope	  protein	  gp41.	  	  The	  cocktail	  was	  used	  to	  detect	  anti-­‐HIV-­‐1	  
antibodies	  from	  a	  panel	  of	  sera	  collected	  from	  HIV-­‐positive	  patients,	  with	  improved	  
signal-­‐to-­‐noise	  ratio	  relative	  to	  the	  gold	  standard	  commercial	  recombinant	  protein	  
antigen.	  	  The	  capture	  agents	  were	  stable	  when	  stored	  as	  a	  powder	  for	  two	  months	  at	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1.1	  PCC	  AGENT	  COCKTAIL	  FOR	  HIV-­‐1	  DIAGNOSTICS	  
	  	   Accurate	  diagnoses	  are	  critical	  for	  effective	  healthcare.	  	  Misdiagnoses	  carry	  large	  
personal	   and	   societal	   costs,	   especially	   in	   cases	   where	   the	   disease	   is	   transmissible	   or	  
carries	  a	  large	  social	  stigma.	  	  HIV	  is	  one	  such	  disease,	  and	  HIV	  misdiagnoses	  can	  lead	  to	  
psychosocial	  difficulties	  and	  have	  dangerous	  public	  health	  implications	  [1].	  	  According	  to	  
the	  World	  Health	  Organization	  (WHO),	  roughly	  40	  million	  people	  were	  living	  with	  HIV	  as	  
of	  the	  end	  of	  2004,	  and	  some	  regions	  have	  adult	  prevalence	  as	  high	  as	  15-­‐39%.	  	  Many	  
countries	  with	  high	  incidence	  of	  HIV	  are	  resource	  limited	  and	  rely	  on	  easy-­‐to-­‐use	  rapid	  
detection	   tests	   for	   diagnosis;	   however,	   the	   performance	   of	   these	   tests	   is	   variable.	   	   A	  
study	  of	  the	  WHO	  HIV	  two-­‐test	  diagnostic	  algorithm,	  where	  two	  positive	  rapid	  detection	  
tests	  are	  used	  alone	   for	  diagnosis,	   showed	  an	  unacceptably	  high	   rate	  of	   false-­‐positive	  
results	  (10.5%),	  likely	  due	  to	  non-­‐selective	  cross	  reactivity	  [2].	  	  	  
	   HIV	   diagnoses	   are	   often	   made	   indirectly	   through	   the	   detection	   of	   anti-­‐HIV	  
antibodies	  [3].	  	  The	  current	  gold	  standard	  detection	  reagents	  are	  biologically-­‐produced,	  
and	  are	  expensive,	  susceptible	  to	  thermal	  and	  biological	  degradation,	  and	  have	  batch	  to	  
batch	   performance	   variability;	   all	   of	   which	   can	   adversely	   affect	   the	   accuracy	   of	  
diagnostic	  assays	  [4,5,6].	  	  Typically	  in	  HIV	  diagnostic	  assays,	  multiple	  immunogenic	  and	  
conserved	  antigens	  from	  HIV	  are	  expressed	  as	  regions	  of	  a	  single	  chimeric	  protein.	  	  That	  
chimeric	   protein	   is	   then	   used	   to	   capture	   specific	   antibodies	   from	   the	   body	   fluid	   (e.g.	  
blood,	   saliva	   or	   urine)	   of	   potentially	   infected	   patients;	   a	   positive	   assay	   result	   implies	  
infection.	   	   However,	   the	   antigen	   has	   been	   shown	   to	   have	   poor	   signal	   to	   noise	   [7],	  
3 
 
possibly	  related	  to	  the	  off-­‐target	  reactivity	  responsible	  for	  false	  negative	  results	  seen	  in	  
rapid	  detection	  tests.	  
	   Robust	  detection	  reagents	  are	  needed	  that	   recognize	   relevant	  biomarkers	  with	  
high	   sensitivity	   and	   selectivity,	   and	   that	  perform	  well	   in	   resource	   limited	  areas	  where	  
controlled	  laboratory	  environments	  are	  not	  readily	  available.	  	  Protein	  Catalyzed	  Capture	  
agents	   (PCC	   agents)	   are	   peptide-­‐based	   detection	   agents	   that	   rival	   the	   affinity	   and	  
selectivity	   of	   biological	   reagents,	   and	   that	   are	   chemically,	   physically,	   and	   biologically	  
robust.	  	  As	  synthetic	  reagents,	  they	  are	  also	  highly	  modular	  and	  can	  be	  easily	  altered	  for	  
incorporation	  into	  different	  assay	  platforms.	  	  Previous	  work	  has	  identified	  a	  number	  of	  
PCC	   agents	   that	   detect	   multiple	   disease	   relevant	   biomarker	   proteins	   through	   the	  
process	  of	  iterative	  in	  situ	  click	  screening	  [8,9,10],	  many	  of	  which	  were	  engineered	  to	  be	  
specifically	   epitope	   targeted,	   and	   some	   of	   which	   have	   inhibiting	   or	   activating	  
functionalities.	  
	   The	  application	  of	  PCC	  agent	  technology	  to	  anti-­‐HIV	  antibody	  detection	  is	  not	  as	  
straightforward	   as	   targeting	   a	   single	   biomarker;	   the	   polyclonal	   diversity	   of	   antibodies	  
across	  patient	  populations	  can	  translate	  into	  large	  variations	  in	  assay	  performance	  from	  
patient	   to	   patient.	   	   To	   selectively	   capture	   the	   diversity	   of	   anti-­‐HIV	   antibodies	   while	  
minimizing	  serological	   cross-­‐reactivity,	  a	  cocktail	  of	  PCC	  agents	  was	  developed	  against	  
multiple	  representative	  anti-­‐HIV	  antibodies.	  	  	  	  	  	  	  
Chapter	  2	  reports	  on	  the	  use	  of	  iterative	  in	  situ	  click	  chemistry	  [8,11]	  to	  prepare	  
a	  cocktail	  of	  chemically	  synthesized	  PCC	  agents	  that	  is	  designed	  to	  sample	  the	  polyclonal	  
diversity	  of	  an	  antibody-­‐based	  immune	  response.	   	  Three	  PCC	  agents,	  derived	  from	  the	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same	  epitope	  on	  HIV-­‐1	  envelope	  protein	  gp41,	  were	  raised	  against	  two	  representative	  
anti-­‐HIV	   antibodies	   to	   create	   a	   cocktail	   of	   capture	   agents	   that	   sample	   the	   variations	  
between	  the	  representative	  antibodies,	  thus	  increasing	  the	  reagent’s	  potential	  to	  detect	  
an	  anti-­‐HIV	  immune	  response	  across	  multiple	  patients.	  	  	  	  
Chapter	  3	   then	  describes	  a	  PCC	  agent-­‐based	  assay	  developed	  to	  detect	  human	  
antibodies	  that	  bind	  a	  conserved	  region	  of	  the	  HIV-­‐1	  envelope	  glycoprotein	  gp41,	  using	  
the	  PCC	  Agent	  cocktail	  described	   in	  Chapter	  2.	   	   The	  performance	   is	   compared	  against	  
the	  gold	  standard	  chimeric	  protein	  antigen	  using	  sera	  collected	  from	  a	  cohort	  of	  HIV-­‐1-­‐
positive	  human	   subjects	   are	   tested,	   plus	   controls.	   	   The	   assay	  was	   also	  used	   to	  detect	  
anti-­‐HIV	   antibodies	   from	   a	   validation	   panel	   of	   HIV-­‐1	   specific	   IgG	   containing	   plasma	  
samples	  that	  were	  rated	  HIGH,	  MED,	  LOW,	  or	  NEG	  in	  accordance	  with	  the	  titer	  of	  anti-­‐
HIV	   antibodies.	   	   Additionally,	   the	   thermal	   stability	   of	   the	   capture	   agent	   cocktail	   is	  
reported,	  with	  an	  eye	  towards	  point-­‐of-­‐care	  HIV	  diagnostics	  assays	  that	  are	  needed	   in	  
environments	  where	  refrigeration	  chains	  may	  not	  exist.	  	  Chapters	  2	  and	  3	  were	  taken	  in	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   Detecting	   the	   immune	   response	   to	   an	   infectious	   agent	   can	  provide	   a	   useful	   in	  
vitro	   diagnostic	   surrogate	   relative	   to	   direct	   pathogen	   detection	   [1].	   	   Such	   assays	   are	  
commonly	   used	   for	   detecting	   HIV	   infection	   because	   of	   its	   characteristic	  
immunopathology	   [2].	   	   Direct	   detection	   of	   HIV	   viral	   RNA	   and	   p24	   antigen	   is	   only	  
effective	  at	  an	  early	  stage	  of	  infection,	  approximately	  2-­‐6	  weeks	  of	  initial	  exposure	  [3,4].	  
Antibodies	  against	  HIV	  envelope	  proteins	  emerge	  in	  patients’	  blood	  around	  3-­‐4	  weeks	  of	  
infection	   [2,5]	   as	   the	   viral	   RNA	   and	   p24	   levels	   decline	   as	   a	   result	   of	   immunocomplex	  
formation	  [6].	  	  The	  high	  serum	  level	  of	  anti-­‐HIV	  IgG	  is	  maintained	  throughout	  the	  course	  
of	   clinical	   latency	   (2-­‐20+	   years),	   during	  which	   time	   viral	   antigens	   are	   under	   detection	  
limits	  until	  the	  onset	  of	  acquired	  immunodeficiency	  syndrome	  (AIDS)	  [2,5].	  	  Typically	  in	  
these	   assays,	   immunogenic	   and	   conserved	   antigens	   from	   the	   HIV	   are	   expressed	   as	  
regions	   of	   a	   single	   chimeric	   protein.	   	   That	   chimeric	   protein	   is	   then	   used	   to	   capture	  
specific	  antibodies	  from	  the	  body	  fluid	  (e.g.	  blood,	  saliva	  or	  urine)	  of	  potentially	  infected	  
patients;	  a	  positive	  assay	  result	   implies	   infection.	   	  However,	  the	  polyclonal	  diversity	  of	  
antibodies	   across	   a	   patient	   population	   can	   translate	   into	   large	   variations	   in	   assay	  
performance	   from	  patient	   to	   patient.	   	   In	   addition,	   the	   chimeric	   recombinant	   proteins	  
are	  biological	   reagents,	  and	  so	  may	  have	   limitations	   related	   to	  shelf	   life	  and	  batch-­‐to-­‐
batch	   variability.	   	   These	   limitations	   can	   adversely	   influence	   the	   performance	   of	   a	  
diagnostic	  test	  [3,5,7],	  especially	  one	  that	  is	  deployed	  in	  harsh	  physical	  environments.	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   Previous	   work	   in	   the	   Heath	   group	   has	   demonstrated	   the	   ability	   to	   selectively	  
target	  biologically	  relevant	  proteins	  with	  PCC	  Agents	  [8,9].	  	  Targeting	  anti-­‐HIV	  antibodies	  
requires	   selective	  detection	  of	   anti-­‐HIV	   antibodies	   over	   other	   IgG	   and	   serum	  proteins	  
while	   maintaining	   sensitivity	   to	   variations	   in	   immune	   response	   across	   patients.	   	   This	  
chapter	  reports	  on	  the	  discovery,	  synthesis,	  and	  characterization	  of	  a	  cocktail	  of	  capture	  
agents	  that	  selectively	  target	  different	  anti-­‐HIV	  antibodies	  to	  increase	  the	  target	  capture	  
probability	  while	  minimizing	  cross	  reactivity	  with	  other	  proteins	  in	  sera.	  	  	  
	  
2.2	  IN	  SITU	  CLICK	  	  
The	  development	  of	  a	  PCC	  Agent	  against	  a	  protein	  target	  utilizes	  the	  target	  itself	  
to	  promote	  the	  1,3-­‐dipolar	  cycloaddition	  between	  an	  acetylene	  and	  an	  azide	  group	  to	  
form	  a	  triazole	  linkage	  (the	  in	  situ	  ‘click’	  reaction)	  [10].	  	  The	  protein	  effectively	  plays	  the	  
role	  of	  an	  extremely	  selective,	  but	  much	  less	  efficient,	  variant	  of	  the	  Cu(I)	  catalyst	  that	  is	  
commonly	  used	  for	  such	  couplings	  [11,12].	  	  For	  the	  present	  work,	  the	  two	  reacting	  
species	  are	  peptides	  –	  one	  peptide	  (the	  anchor)	  is	  a	  chemically	  modified	  variant	  of	  a	  
conserved,	  immunogenic	  epitope	  on	  the	  HIV-­‐1	  gp41	  protein,	  and	  the	  second	  peptide	  is	  
selected	  via	  an	  in	  situ	  click	  screen	  from	  a	  large	  (106	  element)	  one-­‐bead-­‐one-­‐compound	  
(OBOC)	  [13]	  peptide	  library.	  	  The	  protein	  targets	  are	  human	  monoclonal	  antibodies	  





2.3	  ANCHOR	  SELECTION	  	  
The	   PCC	  Agents	   developed	   here	  were	   designed	   to	   capture	   antibodies	   that	   are	  
selective	  for	  residues	  600-­‐612	  (IWCGSGKLICTTA)	  of	  gp41.	  	  Previous	  studies	  have	  shown	  
that	  a	   large	   fraction	  of	  HIV-­‐1-­‐positive	  patients	  develop	  antibodies	  against	   this	  epitope	  
[14,15].	   	   Our	   strategy	   for	   sampling	   the	   polyclonal	   diversity	   of	   such	   antibodies	  was	   to	  
develop	   PCC	   Agents	   that	   exhibited	   both	   differential,	   as	   well	   as	   similar	   avidities	   for	  
human	  monoclonal	  antibodies	  (mAbs)	  raised	  against	  different	  parts	  of	  this	  epitope.	  	  To	  
select	   the	   anchor	   peptides,	   we	   modified	   the	   polypeptide	   fragment	   corresponding	   to	  
residues	  600-­‐612	  of	  gp41	  with	  artificial	  amino	  acids	  at	  multiple	  locations,	  and	  tested	  the	  
ability	  of	   these	  modified	   cyclic	  peptides	   to	  detect	   two	  different	  monoclonal	   anti-­‐gp41	  
antibodies	  3D6	  and	  4B3	  (Polymun,	  Klosterneuburg,	  Austria).	   	  The	  3D6	  mAb	  was	  raised	  
against	  the	  epitope	  SGKLIC,	  whereas	  the	  4B3	  mAb	  was	  raised	  against	  SGKLICTTA.	   	  One	  
anchor	  peptide,	  A21,	  was	  synthesized	  by	  adding	  a	  propargyl	  glycine	  (Pra)	  residue	  at	  the	  
C-­‐terminus	  of	  the	  residues	  600-­‐612	  of	  gp41.	  	  This	  anchor	  peptide	  was	  also	  N-­‐terminally	  
tagged	  with	  a	  polyethylene	  glycol	  (PEG)	  oligomer	  bridge	  and	  a	  biotin	  label.	  	  For	  a	  second	  
anchor	   peptide	   (A22),	   Leu-­‐607	   was	   substituted	   with	   Pra.	   	   A22	   also	   included	   an	   N-­‐
terminal	   PEG-­‐biotin	   label.	   	   A21	   equally	   detected	   3D6	   and	   4B3	   with	   an	   estimated	  
dissociation	  constant	  (Kd)	  of	  1-­‐50	  nM,	  while	  A22	  differentially	  detected	  3D6	  (Kd	  >10	  µM)	  
and	  4B3	  (Kd	  =	  1-­‐50	  nM)	  (Figure	  2.1).	  	  A21	  and	  A22	  were	  then	  separately	  developed	  into	  






The	  in	  situ	  click	  screens	  are	  illustrated	  in	  Scheme	  2.1.	  	  The	  target	  IgG	  is	  incubated	  
with	  an	  excess	  of	  the	  selected	  anchor	  peptide	  and	  a	  large	  OBOC	  library	  at	  4oC	  overnight	  
(see	  Materials	  and	  Methods).	  	  The	  OBOC	  library	  is	  synthesized	  on	  TentaGel	  resin	  (Rapp	  
Polymere,	   Tuebingen,	   Germany),	   and	   is	   a	   comprehensive	   library	   of	   5-­‐mers	  with	   a	   6th	  
amino	  acid	  at	  the	  N-­‐terminus	  presenting	  an	  azide	  functionality.	  	  To	  help	  ensure	  chemical	  
and	   biochemical	   stability,	   the	   OBOC	   library	   is	   comprised	   of	   non-­‐natural	   (D)	  
stereoisomers	  of	  the	  20	  natural	  amino	  acids,	  excluding	  cysteine	  and	  methionine.	  	  The	  in	  
situ	   screen	   is	  designed	   to	   identify	  a	   secondary	   (2o)	  peptide	   that,	  when	  coupled	   to	   the	  









Figure	  2.1.	  Differential	  detection	  of	  3D6	  and	  4B3	  by	  anchor	  ligands.	  	  Relative	  affinities	  of	  
A21	  and	  A22	  for	  3D6	  and	  4B3	  were	  determined	  by	  sandwich	  ELISA.	  Biotinylated	  anchor	  
ligands	   A21	   and	   A22	   were	   immobilized	   on	   streptavidin-­‐coated	   96-­‐well	   plated	   at	   a	  
concentration	  of	  100	  nM,	  and	  incubated	  with	  the	  solutions	  of	  target	  anti-­‐HIV	  antibodies	  
3D6	   and	   4B3	   at	   100	   nM	   in	   TBS.	   	   Captured	   antibody	   was	   detected	   by	   peroxidase-­‐











	   The	  screen	  proceeds	  stepwise.	   	   In	  the	  first	  step	  (not	  shown	   in	  Scheme	  2.1)	  the	  
OBOC	   library	   is	   cleared	   of	   beads	   that	   exhibit	   non-­‐specific	   binding	   to	   alkaline	  
phosphatase-­‐conjugated	  streptavidin	  (SA-­‐AP),	  which	  is	  used	  as	  a	  detection	  reagent	  in	  a	  
later	  step.	   	  Step	  2	   is	  a	   target	  screen,	  and	  so	   is	  designed	  to	  detect	   the	  presence	  of	   the	  
bound	   IgG	   target	   to	   specific	   beads,	   and	   defines	   possible	   hits.	   	   The	   step	   3	   screen	   is	  
designed	  to	  remove	  those	  beads	  from	  the	  pool	  of	  potential	  hits	  that	  also	  exhibit	  binding	  
to	   off-­‐target	   serum	   proteins.	   	   Step	   4	   is	   called	   a	   product	   screen,	   and	   is	   unique	   to	  
sequential	  in	  situ	  click	  screens	  [16].	  	  This	  screen	  is	  designed	  to	  detect	  for	  the	  presence	  of	  
in	  situ	  clicked	  reaction	  products,	  which	  are	  those	  hit	  beads	  containing	  the	  triazole-­‐linked	  
anchor	   peptide.	   	   Typically,	   Step	   2	   yields	   a	   few	   hundred	   hits	   (~0.05%	   of	   the	   OBOC	  
library).	   	   Step	  3	   reduces	   that	  pool	  by	  a	   factor	  of	  2	  or	  3	   to	  about	  100	  hits,	   and	  Step	  4	  
further	   reduces	   the	   number	   of	   hits	   to	   around	   10.	   	   This	   is	   a	   manageable	   number,	  
meaning	  that	  each	  hit	  can	  be	  separately	  synthesized	  as	  a	  biligand	  using	  Cu(I)	  catalyzed	  
click	  chemistry	  to	  couple	  the	  anchor	  and	  2o	  peptides.	  	  A	  complete	  list	  of	  the	  hits	  for	  the	  





Scheme	  2.1.	  Screening	  strategy	  for	  selecting	  capture	  agents	  against	  anti-­‐HIV	  antibodies	  
3D6	  and	  4B3.	   	  The	  flow	  chart	  represents	  the	  use	  of	  the	  A21	  and	  A22	  cyclic	  peptides	  as	  










Table	   2.1.	   Biligand	   screen	   results.	   	   List	   of	   pentapeptide	   “hits”	   from	   OBOC	   biligand	  
screens	   performed	   with	   A21/3D6	   and	   A22/4B3.	   	   The	   selected	   secondary	   ligands	  
corresponding	  to	  (i),	  (ii),	  and	  (iii)	  are	  shown	  in	  red,	  blue,	  and	  green	  respectively	  (shown	  
in	  Figure	  2.2).	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2.5	  BILIGAND	  CHARACTERIZATION	  
	   The	   performance	   of	   these	   biligands	   is	   then	   characterized	   using	  
immunoprecipitation	   (pulldown)	   assays	   detected	   by	   Western	   blotting	   from	   spiked	  
serum	   samples	   for	   specificity	   (data	   not	   shown),	   and	   sandwich	   ELISAs	   and	   surface	  
plasmon	  resonance	  (SPR)	  assays	  for	  affinity	  estimations	  (Figure	  2.3-­‐2.4).	  	  This	  approach	  
yielded	  two	  equivalently	  performing	  biligands	  against	  3D6,	  and	  one	  biligand	  against	  4B3.	  	  
These	  three	  PCC	  agents	   (Figure	  2.2)	  were	  combined,	   in	  equal	  parts,	   to	   form	  a	  capture	  
agent	   cocktail.	   The	   cocktail	   slightly	   outperformed	   both	   the	   standard	   commercial	  
chimeric	  antigen	  and	  A21,	  when	  tested	  against	  healthy	  human	  serum	  spiked	  with	  both	  







Figure	   2.2.	   Structures	   of	   peptide	   ligands	   in	   PCC	   Agent	   cocktail.	   	   Acetylene-­‐presenting	  
anchor	   peptides	   (black)	   were	   derived	   from	   the	   immunogenic	   epitope	   of	   HIV-­‐1	   gp41	  
(residues	   600-­‐612).	   	   A22-­‐nindG	   (i)	   and	   A21-­‐hnpfk	   (ii)	   were	   evolved	   from	   the	   original	  
epitope	   appended	   with	   Pra	   at	   the	   C-­‐terminus	   whereas	   A22-­‐eihny	   (iii)	   utilizes	   the	  
“substituted”	   anchor	   where	   residue	   Leu-­‐607	   is	   replaced	   with	   Pra.	   	   Secondary	   ligand	  
branches	  (colored)	  were	  identified	  from	  the	  in	  situ	  click	  screen	  of	  a	  5-­‐mer	  OBOC	  library	  
presenting	   an	   azide	   functionality.	   	   Biligands	   (i)	   and	   (ii)	  were	   raised	   against	   the	   target	  






Figure	  2.3.	  Apparent	  affinity	  of	  A21	  and	  biligands	  directed	  against	  3D6	  as	  determined	  by	  
SPR.	  	  A.	  Sensorgram	  and	  1st	  order	  Hill	  fit	  to	  affinity	  data	  for	  A21.	  	  B.	  Sensorgram	  and	  1st	  
order	  Hill	   fit	   to	   affinity	  data	   for	  A21-­‐nidnG	   (i).	   	  C.	   Sensorgram	  and	  1st	   order	  Hill	   fit	   to	  




Figure	  2.4.	  Apparent	  affinity	  of	  A22	  and	  biligand	  directed	  against	  4B3	  as	  determined	  by	  
SPR.	  	  A.	  Sensorgram	  and	  1st	  order	  Hill	  fit	  to	  affinity	  data	  for	  A22.	  	  B.	  Sensorgram	  and	  1st	  






Figure	   2.5.	   Performance	   of	   PCC	   agent	   cocktail	   to	   detect	   3D6	   and	   4B3	   from	   human	  
serum.	   	   Comparative	   performance	   of	   the	   PCC	  Agent	   cocktail	   versus	   the	   original	   gp41	  
epitope	   A21	   and	   the	   commercial	   chimeric	   protein	   antigen	   was	   tested	   by	   a	   sandwich	  
ELISA.	  	  Target	  antibodies	  3D6	  and	  4B3	  (4	  nM	  each)	  were	  both	  spiked	  into	  diluted,	  HIV-­‐
free	  human	  serum	  (1%	  v/v	  in	  TBS),	  and	  captured	  antibody	  was	  detected	  by	  peroxidase-­‐











2.6	  MATERIALS	  AND	  METHODS	  
2.6.1	  Anchor	  Synthesis	  
	   The	  anchor	  peptides	  A21	  and	  A22	  were	   synthesized	  C	  →	  N	  on	  200-­‐300	  mgs	  of	  
Rink	   amide	   resin	   (AnaSpec,	   Fremont,	   CA)	   with	   a	   Titan	   peptide	   synthesizer	   using	  
standard	   Fmoc	   chemistry	   [17].	   	   The	   synthesis	   used	   Fmoc	   and	   side	   chain	   protected	   L	  
amino	   acids	   (Aaptec,	   Louisville,	   KY),	   Fmoc	   protected	   propargylglycine	   (Pra)	   (Aaptec,	  
Louisville,	  KY),	  PEG5	  (EMD	  Millipore,Germany),	  and	  biotin	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO).	  	  
The	  finished	  peptides	  were	  side-­‐chain	  deprotected	  and	  cleaved	  from	  resin	  in	  a	  mixture	  
of	  95%	  v/v	  trifluoroacetic	  acid	  (TFA)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  5%	  v/v	  dH2O,	  and	  5%	  
triethylsilane	   (TES)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO),	   and	   precipitated	   in	   diethyl	   either.	  	  
Cu(Phen)3	   stock	   solution	  was	  prepared	  by	  mixing	   150	  mM	  Cu(II)	   sulfate	  pentahydrate	  
(Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   and	   500	   mM	   1,10-­‐phenanthroline	   (Sigma-­‐Aldrich,	   St.	  
Louis,	  MO)	  in	   	  4:1	  H2O:Ethanol.	  The	  ether-­‐precipitated	  ligands	  were	  cyclized	  by	  stirring	  
the	  cleaved	  peptides	  dissolved	   in	  ~5	  mL	  acetonitrile	   (ACN)	  overnight	  with	  1	  mL	  of	   the	  
Cu(Phen)3	   stock	   solution.	   The	   cyclization	   mixtures	   were	   lyophilized,	   and	   the	   final	  
peptide	  products	  were	  purified	  using	  reverse	  phase	  (RP)	  HPLC	  on	  a	  Kinetex	  5µ	  XB-­‐C18	  
250	  x	  4.6	  mm	  prep	  column	  (Phenomenex,	  Torrance,	  CA).	  	  MALDI-­‐TOF	  MS:	  A21:	  Expected	  
mass	   [M+H]+	  =	  2006.96,	   Observed	   mass	   [M+H]+	  =	  2006.24.	   A22:	   Expected	   mass	  





2.6.2	  OBOC	  Screens	  
	   All	  screens	  used	  naïve	  one-­‐bead-­‐one-­‐compound	  (OBOC)	  D-­‐pentapeptide	  libraries	  
on	   TentaGel	   resin	   (TG)	   (Rapp	   Polymere,	   Tuebingen,	   Germany)	   of	   the	   form	   NH2-­‐Az4-­‐
X1X2X3X4X5-­‐TG,	  excluding	  cysteine	  and	  methionine,	  where	  Az4	  is	  L-­‐azidolycine.	  	  Libraries	  
were	  synthesized	  on	  a	  Titan	  peptide	  synthesizer	  (Aaptec,	  Louisville,	  KY)	  using	  a	  split/mix	  
method,	   and	   couplings	   were	   done	   using	   standard	   Fmoc	   SPPS	   chemistry	   in	   N-­‐
methylpyrrolidone	  (NMP).	  	  	  
	  
A21	  with	  3D6	  
	   Screening	   against	   3D6	   was	   carried	   out	   in	   four	   main	   steps:	   pre-­‐clear,	   target	  
screen,	  anti-­‐screen,	  and	  product	  screen.	   	  Step	  1	  preclear:	  400	  mg	  of	  OBOC	  library	  was	  
blocked	  in	  5%	  w/v	  dry	  milk	  in	  Tris	  buffered	  saline	  (TBS)	  (25	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  
10	  mM	  MgCl2,	  pH	  7.6)	  for	  2	  hr	  at	  room	  temperature,	  and	  then	  incubated	  with	  1:10,000	  
phosphatase-­‐conjugated	   streptavidin	   (SA-­‐AP,	   Promega,	  Madison,	  WI)	   in	   0.5%	  w/v	   dry	  
milk	   in	  TBS	  for	  1	  hr.	   	  The	  beads	  were	  washed	   in	  high	  salt	  buffer	   (25	  mM	  Tris-­‐HCl,	  750	  
mM	  NaCl,	  10	  mM	  MgCl2,	  pH	  7.6)	  for	  1	  hr,	  and	  then	  developed	  with	  BCIP/NBT	  (Promega,	  
Madison,	  WI)	  in	  BCIP	  buffer	  (100	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  1	  mM	  MgCl2,	  pH	  9).	  	  	  After	  
20	   minutes,	   the	   reaction	   was	   quenched	   with	   conc.	   HCl,	   and	   the	   purple	   beads	   were	  
discarded.	  	  The	  remaining	  library	  was	  decolorized	  in	  NMP,	  dried	  with	  methanol	  (MeOH)	  
and	  dichloromethane	  (DCM),	  and	  then	  swelled	  and	  blocked	  in	  5%	  w/v	  dry	  milk	  in	  TBS	  for	  
2	  hr	  at	  room	  temperature.	  	  Step	  2	  target	  screen:	  4	  mL	  of	  a	  solution	  containing	  11.4	  µM	  
A21	  and	  147	  nM	  3D6	   in	  0.5%	  w/v	  dry	  milk	   in	  TBS	  was	  added	   to	   the	  precleared	  OBOC	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library,	  and	  the	   in	  situ	   click	   reaction	  was	  allowed	  to	  proceed	  overnight	  at	  4°C.	   	  Bound	  
target	   was	   probed	   with	   1:10,000	   AP-­‐conjugated	   rabbit	   anti-­‐human	   IgG	   Fc	   (Thermo	  
Scientific,	  Rockford,	   IL)	   in	  0.5%	  w/v	  dry	  milk	   in	  TBS	  for	  1	  hr	  at	  room	  temperature.	  The	  
beads	   were	   then	   washed	   in	   high	   salt	   buffer	   for	   1	   hr	   at	   room	   temperature,	   and	  
developed	  with	  BCIP/NBT	  in	  BCIP	  buffer.	  	  The	  reaction	  was	  quenched	  after	  20	  minutes	  
with	  conc.	  HCl,	  and	  the	  purple	  beads	  were	  retained	  and	  decolorized	  in	  NMP	  and	  dried	  
with	  MeOH	  and	  DCM.	  	  The	  hit	  beads	  were	  then	  stripped	  of	  all	  bound	  protein	  by	  washing	  
with	   7.5	  M	  Guanidine-­‐HCl	   (pH	  2)	   for	   2	   hr	   at	   room	   temperature,	   rinsed	   10	   times	  with	  
water,	  and	  then	  blocked	  in	  5%	  w/v	  dry	  milk	  in	  TBS	  for	  2	  hr	  at	  room	  temperature.	  	  Step	  3	  
anti-­‐screen:	   	  A	  solution	  of	  1%	  v/v	  human	  serum	  (Omega	  Scientific,	  Tarzana,	  CA)	  in	  TBS	  
was	  incubated	  with	  the	  hit	  beads	  from	  Step	  2	  for	  1	  hr	  at	  room	  temperature.	  	  Off-­‐target	  
human	  antibodies	  bound	  to	  the	  beads	  were	  probed	  with	  1:10,000	  AP-­‐conjugated	  rabbit	  
anti-­‐human	  IgG	  Fc	  in	  0.5%	  w/v	  dry	  milk	  in	  TBS	  for	  1	  hr	  at	  room	  temperature.	  The	  beads	  
were	   then	  washed	   in	   high	   salt	   buffer	   for	   1	   hr,	   and	   developed	  with	   BCIP/NBT	   in	   BCIP	  
buffer.	   	   The	   reaction	  was	   quenched	   after	   20	  minutes	  with	   conc.	   HCl,	   and	   the	   purple	  
beads	  were	  discarded.	   	  The	  remaining	  beads	  were	  decolorized	   in	  NMP	  and	  dried	  with	  
MeOH	   and	   DCM.	   	   The	   anti-­‐screened	   beads	   were	   swelled	   in	   water	   and	   washed	   with	  
Guanidine-­‐HCl	   for	   2	   hr	   at	   room	   temperature,	   rinsed	   10	   times	   with	   water,	   and	   then	  
blocked	  in	  5%	  w/v	  dry	  milk	  in	  TBS	  for	  2	  hr	  at	  room	  temperature.	  	  Step	  4	  product	  screen:	  
The	  beads	  were	   incubated	   for	  1	  hr	  at	   room	  temperature	  with	  1:10,000	  SA-­‐AP	   in	  0.5%	  
w/v	   dry	  milk	   in	   TBS,	  washed	   for	   1	   hr	  with	   high	   salt	   buffer,	   and	   then	   developed	  with	  
BCIP/NBT	  in	  BCIP	  buffer	  for	  20	  minutes.	  	  The	  reaction	  was	  quenched	  with	  conc.	  HCl,	  and	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the	  purple	  beads	  were	  retained	  and	  sequenced	  using	  a	  Procise	  CLC	  Edman	  Degradation	  
Protein	  Sequencing	  System	  (Applied	  Biosystems,	  Kingston,	  RI).	  	  	  
	  
A22	  with	  4B3	  
	   Screening	  against	  4B3	  was	  carried	  out	  similarly	   to	   that	  described	   for	  3D6,	  with	  
two	  exceptions.	  	  In	  Step	  2,	  the	   in	  situ	  click	  reaction	  solution	  contained	  10	  µM	  A22	  and	  
430	   nM	   4B3	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS.	   	   In	   Step	   3,	   the	   beads	   were	   anti-­‐screened	  
against	  0.1%	  v/v	  human	  serum	  in	  TBS	  spiked	  with	  430	  nM	  3D6.	  
	  
2.6.3	  Biligand	  Synthesis	  
Pra-­‐OtBu	  
	   The	  C-­‐terminally	  protected	  Pra	  molecule	  used	  in	  the	  synthesis	  of	  (i)	  and	  (ii)	  was	  
made	   by	   refluxing	   Fmoc-­‐L-­‐Pra-­‐OH	   (Aaptec,	   Louisville,	   KY)	   with	   tert-­‐butyl-­‐
tricholroacetamide	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO)	  at	  50°C	  for	  3	  hr	  in	  DCM.	  	  The	  formed	  
product	  was	  separated	  from	  unreacted	  species	  on	  a	  silica	  flash	  column	  in	  DCM.	  
	  
Peptides	  (i)	  and	  (ii)	  
	   The	  secondary	   ligands	   including	  N-­‐terminal	  Az4	   for	   (i)	  and	   (ii)	  were	  synthesized	  
C	  →	  N	   on	   200-­‐300	   mgs	   of	   Rink	   amide	   resin	   with	   a	   Titan	   peptide	   synthesizer	   using	  
standard	  Fmoc	  chemistry.	   	  The	  synthesis	  used	  Fmoc	  and	  side	  chain	  protected	  D	  amino	  
acids	  and	  L-­‐Az4	  (Aaptec,	  Louisville,	  KY).	  	  Fmoc-­‐	  and	  C-­‐terminally	  protected	  Pra	  (Pra-­‐OtBu)	  
was	   clicked	  on-­‐bead	   to	   the	  azide	   side	   chain	  of	  Az4	  by	  adding	  equal	  molar	  amounts	  of	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Pra-­‐OtBu,	  Cu(I)	  iodide	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  and	  L-­‐ascorbic	  acid	  (Sigma-­‐Aldrich,	  
St.	  Louis,	  MO),	  in	  2x	  excess	  to	  the	  azide	  on	  bead.	  	  The	  click	  mixture	  was	  agitated	  in	  20%	  
v/v	  piperidine	   in	  NMP	  for	  3	  hr	  at	   room	  temperature,	  and	   the	  copper	  was	  chelated	  by	  
repeated	   washing	   with	   10%	   w/v	   sodium	   diethylduthiocarbamate	   trihydrate	   (Sigma-­‐
Aldrich,	   St.	   Louis,	  MO)	   and	  10%	  v/v	  N,N-­‐diisopropylethylamine	   (DIEA	   )	   (Sigma-­‐Aldrich,	  
St.	  Louis,	  MO)	  in	  NMP	  until	  the	  beads	  were	  clear.	  	  The	  Fmoc	  deprotected	  Pra	  was	  then	  
the	  starting	  point	  for	  the	  remainder	  of	  the	  anchor	  component	  of	  each	  ligand,	  including	  
N-­‐terminal	  PEG5	  and	  biotin.	   	  The	  anchor	  components	  were	  synthesized	  using	  standard	  
Fmoc	   chemistry	  with	  protected	   L	   amino	   acids.	   	   The	   finished	  peptides	  were	   side-­‐chain	  
deprotected	  and	  cleaved	  from	  resin	  in	  95:5:5	  TFA:dH2O:TES,	  then	  precipitated	  in	  diethyl	  
either.	   	   The	   ligands	  were	   cyclized	   by	   stirring	   the	   cleaved	   peptides	   dissolved	   in	   ~5	  mL	  
ACN	  overnight	  with	  1	  mL	  of	  the	  Cu(phen)3	  stock	  solution.	  	  The	  cyclization	  mixtures	  were	  
lyophilized,	  and	  the	  final	  peptide	  products	  were	  purified	  using	  RP-­‐HPLC	  on	  a	  Kinetex	  5µ	  
XB-­‐C18	   250	   x	   4.6	   mm	   prep	   column.	   	   MALDI-­‐TOF	   MS:	   (i):	   Expected	   mass	  
[M+H]+	  =	  2733.30,	   Observed	   mass	   [M+H]+	  =	  2733.64.	   (ii):	   Expected	   mass	  
[M+H]+	  =	  2843.40,	  Observed	  mass	  [M+H]+	  =	  2843.60.	  
	  
Peptide	  (iii)	  
	   A22	  was	  synthesized,	  cyclized,	  and	  purified	  as	  described	  above.	   	  The	  secondary	  
ligand	   component	   including	   N-­‐terminal	   Az4	   for	   (iii)	   was	   synthesized	   C	  →	  N	   on	   Rink	  
amide	   resin	   with	   a	   Titan	   peptide	   synthesizer	   using	   standard	   Fmoc	   chemistry.	   	   The	  
synthesis	   used	   Fmoc	   and	   side	   chain	   protected	   D	   amino	   acids	   and	   L-­‐Az4.	   Resulting	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secondary	   peptide	   was	   side-­‐chain	   deprotected	   and	   cleaved	   from	   resin	   in	   95:5:5	  
TFA:dH2O:TES,	  precipitated	  in	  diethyl	  either,	  and	  purified	  using	  RP-­‐HPLC	  on	  a	  Kinetex	  5µ	  
XB-­‐C18	  250	  x	  4.6	  mm	  prep	  column.	  	  The	  purified	  secondary	  peptide	  was	  clicked	  to	  A22	  
in	  solution	  by	  mixing	  with	  2x	  molar	  excess	  of	  A22,	  10x	  Cu(I)	  iodide,	  50x	  L-­‐ascorbic	  acid,	  
and	  4x	  Tris[(1-­‐benzyl-­‐1H-­‐1,2,3-­‐triazol-­‐4-­‐yl)methyl]amine	  (TBTA)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  
MO)	  in	  5:1	  NMP:dH2O	  and	  stirring	  overnight	  at	  room	  temperature.	  	  The	  clicked	  biligand	  
product	  was	  purified	  from	  the	  reaction	  mixture	  by	  RP-­‐HPLC	  on	  a	  Kinetex	  5µ	  XB-­‐C18	  250	  
x	   4.6	   mm	   prep	   column.	   	   Expected	   mass	   [M+H]+	  =	  2720.31,	   observed	   mass	  
[M+H]+	  =	  2720.5.	  
	  
Scaling	  up	  (iii)	  
	  	   The	   secondary	   ligands	   including	   N-­‐terminally	   Boc-­‐protected	   Az4	   for	   (iii)	   was	  
synthesized	  C	  →	  N	  on	  Rink	  amide	  resin	  with	  a	  Titan	  peptide	  synthesizer	  using	  standard	  
Fmoc	  chemistry.	  	  The	  synthesis	  used	  Fmoc	  and	  side	  chain	  protected	  D	  amino	  acids	  and	  
L-­‐Az4	   (AnaSpec,	   Fremont,	   CA).	   	   Truncated	   A22	   (Pra-­‐ICTTA)	   was	   synthesized	   C	  →	  N	   on	  
Sieber	   amide	   resin	   (ChemPep,	   Wellington,	   FL)	   with	   a	   Liberty	   1	   microwave	   peptide	  
synthesizer	   (CEM,	  Matthews,	  NC)	  using	   standard	  Fmoc	  chemistry.	   	   The	   synthesis	  used	  
Fmoc	  and	  side	  chain	  protected	  L	  amino	  acids	  and	  Fmoc-­‐L-­‐Pra.	  	  Fully	  protected	  truncated	  
A22	  was	   cleaved	   from	   the	   resin	  with	   1%	   v/v	   TFA	   in	  DCM,	   and	   neutralized	  with	  DIEA.	  	  
Solvent	  was	  removed	  using	  a	  rotary	  vacuum	  evaporator	  and	  the	  protected	  peptide	  was	  
purified	   by	   RP-­‐HPLC	   on	   a	   Kinetex	   5µ	   XB-­‐C18	   250	   x	   4.6	   mm	   prep	   column.	   	   Resulting	  
truncated	   A22	   was	   clicked	   on-­‐bead	   to	   the	   secondary	   peptide	   through	   the	   azide	   side	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chain	   of	   Boc-­‐Az4	   by	   adding	   equal	   molar	   amount	   of	   the	   protected	   truncated	   A22,	   2x	  
molar	  excess	  of	  Cu(I)	  iodide,	  and	  2x	  excess	  of	  L-­‐ascorbic	  acid	  to	  the	  azide	  on	  bead.	  	  The	  
click	  mixture	  was	  agitated	  in	  20%	  v/v	  piperidine	  in	  NMP	  overnight	  at	  room	  temperature,	  
and	   then	   the	   copper	   was	   chelated	   by	   repeated	   washing	   with	   10%	   w/v	   sodium	  
diethyldithiocarbamate	  trihydrate	  and	  10%	  v/v	  DIEA	  in	  NMP	  until	  the	  beads	  were	  clear.	  	  
The	  Fmoc	  deprotected	  Pra	  was	  then	  the	  starting	  point	  for	  the	  remainder	  of	  the	  anchor	  
component,	   including	  N-­‐terminal	  PEG5	  and	  biotin	   (Biotin-­‐PEG5-­‐IWGCSGK).	   	  The	  anchor	  
components	  were	  synthesized	  using	  standard	  Fmoc	  chemistry	  with	  protected	  L	  amino	  
acids.	   	   The	   finished	   peptide	   was	   N-­‐terminal	   and	   side-­‐chain	   deprotected	   and	   cleaved	  
from	  resin	   in	  95:5:5	  TFA:dH2O:TES,	   then	  precipitated	   in	  diethyl	  either.	   	  The	   ligand	  was	  
cyclized	  by	  stirring	  the	  cleaved	  peptide	  dissolved	  in	  ~5	  mL	  ACN	  overnight	  with	  1	  mL	  of	  
the	  Cu(phen)3	   stock	   solution.	   	   The	   cyclization	  mixtures	  were	   lyophilized,	   and	   the	   final	  




Anchor	  binding	  ELISA	  
	   Biotinylated	   anchor	   peptide	   was	   immobilized	   on	   streptavidin-­‐coated	   96-­‐well	  
plates	  (Thermo	  Scientific	  Pierce,	  Rockford,	  IL)	  at	  a	  concentration	  of	  100	  nM	  in	  TBS.	  	  The	  
plates	  were	  blocked	  with	  5%	  w/v	  dry	  milk	   in	  TBS,	  and	   then	   the	  anchor	  peptides	  were	  
incubated	   with	   either	   100	   nM	   3D6	   or	   4B3	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   at	   room	  
temperature	  for	  1	  hr.	  	  Bound	  antibody	  was	  probed	  with	  horseradish	  peroxidase	  (HRP)-­‐
28 
 
conjugated	   mouse	   monoclonal	   antibody	   to	   human	   IgG	   Fc	   (Abcam,	   Cambridge,	   MA),	  
diluted	   1:10,000	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   for	   1	   hr	   at	   room	   temperature.	   	   The	  
colorimetric	   assay	   was	   developed	   with	   TMB	   substrate	   (KPL,	   Gaithersburg,	   MD),	   then	  
quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm.	  	  
	  
Surface	  Plasmon	  Resonance	  
	   SPR	   experiments	  were	   performed	   on	   a	   Biacore	   T200	   instrument.	   	   Biotinylated	  
peptides	   were	   immobilized	   on	   streptavidin-­‐coated	   sensor	   chips	   (GE	   Healthcare	  
Biosciences,	  Pittsburg,	  PA)	  at	  R.U.	  values	  ranging	  from	  7-­‐12.	  	  4B3	  or	  3D6	  was	  flowed	  at	  
various	  concentrations	  in	  1x	  HBS-­‐EP	  buffer	  (GE	  Healthcare	  Biosciences,	  Pittsburgh,	  PA),	  
and	  affinity	  curves	  were	  fit	  using	  the	  default	  settings	  of	  the	  Biacore	  evaluation	  software.	  	  	  
	  
Cocktail	  binding	  ELISA	  
	   Recombinant	   multi-­‐epitope	   chimeric	   HIV	   antigen	   (“chimera”)	   (BioLink	  
International,	  Lisle,	  IL)	  was	  chemically	  biotinylated	  using	  ChromaLink	  Biotin	  Labeling	  Kit	  
(Solulink,	  San	  Diego,	  CA)	  according	  to	  the	  manufacturer’s	   instructions,	  using	  10x	  molar	  
excess	   of	   the	   ChromaLink	   biotinylation	   reagent	   to	   the	   buffer-­‐exchanged	   protein.	  
Streptavidin-­‐coated	  96-­‐well	  plates	  were	  saturated	  with	  the	  biotinylated	  biligand	  cocktail	  
or	  chimera	  using	  1	  uM	  solutions	  in	  TBS.	  	  The	  plates	  were	  blocked	  with	  5%	  w/v	  dry	  milk	  
in	  TBS,	  and	  then	  the	  capture	  reagents	  were	  incubated	  with	  either	  1%	  v/v	  human	  serum	  
or	  a	  mixture	  of	  4	  nM	  each	  3D6	  and	  4B3	  spiked	  in	  1%	  v/v	  human	  serum	  	  in	  TBS	  at	  room	  
temperature	   for	   1	   hr.	   	   Bound	   antibody	   was	   probed	   with	   HRP-­‐conjugated	   mouse	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monoclonal	  antibody	  to	  human	  IgG	  Fc,	  diluted	  1:15,000	  in	  0.5%	  w/v	  dry	  milk	  in	  TBS	  for	  1	  
hr	   at	   room	   temperature.	   	   The	   colorimetric	   assay	  was	   developed	  with	   TMB	   substrate,	  
then	  quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm	  (A450).	  	  The	  A450	  for	  each	  sample	  is	  
normalized	   against	   the	   A450	   for	   the	   serum	   control,	   to	   yield	   a	   measurement	   of	   the	  
signal-­‐to-­‐noise	  ratio	  of	  the	  assay.	  	  	  
	  
2.7	  CONCLUSION	  
	   Described	   in	   this	   chapter	   is	   a	   method	   for	   developing	   a	   PCC	   Agent	   cocktail	   to	  
capture	  the	  diversity	  of	  human	  antibodies	  generated	  in	  response	  to	  an	  infectious	  agent,	  
with	  specific	  application	  to	  HIV.	  	  The	  components	  of	  the	  cocktail	  were	  raised	  against	  4B3	  
and	  3D6,	  two	  representative	  anti-­‐HIV	  antibodies,	  and	  individual	  and	  collective	  binding	  of	  
the	  capture	  agents	  to	  the	  target	  antibodies	  was	  characterized.	  	  The	  cocktail	  displayed	  a	  
moderately	  enhanced	  performance	   compared	   to	   the	  original	   gp	  41	  epitope	   (A21)	  and	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HIV	  diagnostic	  assays	  typically	  use	  chimeric	  proteins	  comprised	  of	  immunogenic	  
and	  conserved	  antigens	   from	   the	  HIV	   to	   capture	   specific	   anti-­‐HIV	  antibodies	   from	   the	  
body	  fluid	  of	  potentially	  infected	  patients.	  	  However,	  the	  biologically	  produced	  chimeric	  
recombinant	  proteins	  are	  susceptible	  to	  thermal,	  chemical,	  and	  biological	  degradation,	  
as	   well	   as	   batch	   to	   batch	   variability.	   	   These	   limitations	   can	   adversely	   influence	   the	  
performance	   of	   a	   diagnostic	   test	   [1,2,3],	   especially	   when	   used	   outside	   of	   controlled	  
laboratory	  settings.	  
This	  chapter	  explores	  the	  ability	  of	  the	  PCC	  Agent	  cocktail	  described	  in	  Chapter	  2	  
to	   detect	   anti-­‐HIV	   antibodies	   from	   human	   sera	   as	   compared	   to	   that	   of	   a	   standard	  
recombinant	   chimeric	   antigen	   like	   those	   typically	   used	   in	   anti-­‐HIV	   antibody	   detection	  
assays.	   	  The	  chimeric	  protein	  used	  contained	  a	   fragment	  of	  HIV-­‐1	  gp41	   (residues	  546-­‐
692),	   the	   “O”	   group	   HIV-­‐1	   gp41	   immunodominant	   region	   (residues	   580-­‐623),	   and	   a	  
fragment	   of	   HIV-­‐2	   gp36	   (residues	   591-­‐617).	   	   A	   good	   performance	   of	   this	   chimeric	  
antigen	   has	   been	   reported	   elsewhere	   [4].	   	   Two	   sets	   of	   samples	   were	   assayed,	   one	  
clinical	   and	   one	   commercial.	   	   In	   both	   cases	   the	   PCC	  Agent	   cocktail	   showed	   increased	  
average	  signal	  to	  noise	  compared	  to	  the	  chimeric	  antigen.	  
	  
3.2	  PATIENT	  SAMPLE	  ASSAY	  
The	   PCC	   Agent	   cocktail	   and	   the	   standard	   antigen	  were	   co-­‐evaluated	   against	   a	  
panel	   of	   clinical	   samples	   using	   sandwich	   ELISAs.	   	   Serum	   samples	  were	   collected	   from	  
nine	   HIV-­‐1-­‐positive	   patients	   in	   Southern	   California.	   	   For	   the	   comparison	   assays,	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streptavidin-­‐coated	   96-­‐well	   plates	   were	   saturated	   with	   the	   PCC	   Agent	   cocktail	   or	  
chemically	  biotinylated	  chimera	  in	  triplicates.	  	  Serum	  samples	  were	  diluted	  to	  1%	  v/v	  in	  
Tris-­‐buffered	   saline	   (TBS)	   supplemented	   with	   0.1%	   w/v	   bovine	   serum	   albumin	   (BSA),	  
and	   incubated	   in	   the	   wells	   for	   1	   hr	   at	   room	   temperature.	   	   Unbound	   proteins	   were	  
washed	   off	   and	   captured	   IgG	   was	   detected	   with	   a	   peroxidase-­‐conjugated	   mouse	  
monoclonal	  anti-­‐human	  IgG-­‐Fc	  antibody.	   	  The	  comparison	  assay	  results	  for	  the	  patient	  
serum	  samples	  along	  with	  a	  healthy	  control	  are	  shown	  in	  Figure	  3.1.	  	  The	  signal-­‐to-­‐noise	  
(S/N)	   ratio	   in	   these	  assays	   is	  defined	  as	   the	  measured	  ELISA	   signal	   for	  a	  given	  patient	  
sample,	  divided	  by	   that	   for	   the	  healthy	  control.	   	  The	  PCC	  Agent	  cocktail	  performed	  at	  
least	  as	  well,	  and	  typically	  much	  better,	  than	  the	  standard	  chimeric	  protein	  antigen.	  	  The	  
average	   S/N	   improvement	   by	   the	   cocktail	   PCC	   agent	   over	   the	   chimeric	   antigen	  was	   a	  











Figure	  3.1.	  Comparative	  performance	  of	  the	  PCC	  Agent	  cocktail	  versus	  the	  commercial	  
chimeric	  protein,	  using	  sandwich	  ELISAs	  to	  detect	  anti-­‐HIV-­‐1	   IgGs	  from	  a	  panel	  of	  sera	  
samples	  collected	  from	  nine	  HIV-­‐positive	  patients.	  	  The	  absorbance	  at	  450	  nm	  (A450)	  for	  
each	   sample	   is	   normalized	   against	   the	   A450	   for	   the	   healthy	   control,	   to	   yield	   a	  
measurement	  of	  the	  signal-­‐to-­‐noise	  ratio	  of	  the	  assay.	  	  The	  PCC	  Agent	  cocktail,	  which	  is	  
designed	  to	  capture	  a	  subset	  of	  anti-­‐gp41	  IgGs,	  exhibits	  superior	  performance	  for	  every	  
sample,	   even	   though	   the	   chimeric	   protein	   is	   designed	   to	   capture	   antibodies	   against	  
multiple	   HIV-­‐1-­‐associated	   epitopes	   (those	   containing	   fragments	   of	   HIV-­‐1	   gp41,	   “O”	  
group	  HIV-­‐1	  gp41	   immunodominant	   region,	  and	  HIV-­‐2	  gp39).	   	  For	   the	  assays,	   the	  PCC	  
agent	  cocktail	  and	  the	  biotinylated	  chimeric	  antigen	  were	  immobilized	  on	  a	  streptavidin-­‐
coated	  96-­‐well	  plate	  and	  incubated	  with	  diluted	  patient	  serum	  (1%	  v/v).	  	  Captured	  anti-­‐






3.3	  PATH	  SAMPLE	  ASSAY	  
The	  PCC	  Agent	  cocktail	  and	  the	  standard	  antigen	  were	  also	  co-­‐evaluated	  against	  a	  panel	  
of	   commercial	   samples.	   	   Serum	   samples	   from	   individual	   patients	   containing	   high,	  
medium,	   or	   low	   titers	   of	   anti-­‐HIV	   antibodies	   were	   obtained	   from	   SeraCare,	   through	  
PATH	  of	  POC	  diagnostics	  program	  funded	  by	  the	  Bill	  and	  Melinda	  Gates	  Foundation.	  	  For	  
the	  comparison	  assays,	  streptavidin-­‐coated	  96-­‐well	  plates	  were	  saturated	  with	  the	  PCC	  
Agent	   cocktail	   or	   chemically	   biotinylated	   chimera	   in	   triplicates.	   	   Serum	   samples	  were	  
diluted	   to	   1%	   v/v	   in	   Tris-­‐buffered	   saline	   (TBS)	   supplemented	   with	   0.1%	   w/v	   bovine	  
serum	   albumin	   (BSA),	   and	   incubated	   in	   the	   wells	   for	   1	   hr	   at	   room	   temperature.	  	  
Unbound	  proteins	  were	  washed	  off	  and	  captured	  IgG	  was	  detected	  with	  a	  peroxidase-­‐
conjugated	   mouse	   monoclonal	   anti-­‐human	   IgG-­‐Fc	   antibody.	   	   The	   comparison	   assay	  
results	  for	  the	  serum	  samples	  are	  shown	  in	  Figure	  3.2.	  	  The	  signal-­‐to-­‐noise	  (S/N)	  ratio	  in	  
these	  assays	   is	  defined	  as	  the	  measured	  ELISA	  signal	   for	  a	  given	  high,	  medium,	  or	   low	  
titer	  sample,	  divided	  by	  that	  for	  the	  respective	  healthy	  control.	  	  The	  PCC	  Agent	  cocktail	  
generally	   outperformed	   the	   standard	   chimeric	   protein	   antigen,	  with	   the	   exception	   of	  
the	  low	  titer	  samples.	  	  The	  reasons	  for	  this	  are	  not	  entirely	  clear.	  	  However,	  the	  average	  
S/N	   improvement	  by	   the	  cocktail	  PCC	  agent	  over	   the	  chimeric	  antigen	  was	  a	   factor	  of	  







Figure	  3.2.	  Comparative	  performance	  of	  the	  PCC	  Agent	  cocktail	  versus	  the	  commercial	  
chimeric	  protein,	  using	  sandwich	  ELISAs	  to	  detect	  anti-­‐HIV-­‐1	  IgGs	  from	  a	  panel	  of	  HIV-­‐1	  
specific	   IgG	   containing	   plasma	   samples	   provided	   by	   PATH.	   	   The	   samples	   were	   rated	  
HIGH,	  MED,	  or	  LOW	  in	  accordance	  with	  the	  titer	  of	  anti-­‐HIV	  antibodies,	  and	  pooled	  HIV	  
negative	  sera	  samples	  were	  used	  as	  a	  control	  (NEG).	  	  The	  absorbance	  at	  450	  nm	  (A450)	  
for	   each	   sample	   is	   normalized	   against	   the	   A450	   for	   the	   healthy	   control,	   to	   yield	   a	  
measurement	  of	  the	  signal-­‐to-­‐noise	  ratio	  of	  the	  assay.	  	  The	  PCC	  Agent	  cocktail,	  which	  is	  
designed	  to	  capture	  a	  subset	  of	  anti-­‐gp41	  IgGs,	  exhibits	  superior	  performance	  for	  every	  
sample,	   even	   though	   the	   chimeric	   protein	   is	   designed	   to	   capture	   antibodies	   against	  
multiple	   HIV-­‐1-­‐associated	   epitopes	   (those	   containing	   fragments	   of	   HIV-­‐1	   gp41,	   “O”	  
group	  HIV-­‐1	  gp41	   immunodominant	   region,	  and	  HIV-­‐2	  gp39).	   	  For	   the	  assays,	   the	  PCC	  
agent	  cocktail	  and	  the	  biotinylated	  chimeric	  antigen	  were	  immobilized	  on	  a	  streptavidin-­‐
coated	  96-­‐well	  plate	  and	  incubated	  with	  diluted	  patient	  serum	  (1%	  v/v).	  	  Captured	  anti-­‐
HIV	  antibodies	  were	  detected	  using	  peroxidase-­‐conjugated	  anti-­‐human	  IgG	  antibody.	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3.4	  STABILITY	  ASSAY	  
We	   then	   tested	   the	   PCC	   Agents	   for	   thermal	   stability.	   	   The	   PCC	   Agent	   cocktail	  
component	  (iii)	  were	  synthesized	  at	  a	  large	  scale	  for	  an	  academic	  setting	  (~7	  mg,	  Figure	  
3.3)	  and	   the	   lyophilized	   	   samples	  were	   stored	  under	  N2	  at	  25°C,	  37°C,	  or	  57°C	   for	   	  58	  
days.	   	   The	   samples	   were	   then	   analyzed	   by	   HPLC	   to	   determine	   the	   presence	   of	   any	  
degradation	   product.	   	   The	   traces	   of	   the	   peptide	   at	   each	   temperature	   are	   nearly	  
identical,	   indicating	   little	   to	   no	  degeneration	   at	   these	   temperatures	   (Figure	   3.3).	   	   The	  
performance	   of	   these	   stored	   PCC	   Agents	   was	   then	   also	   tested	   in	   an	   ELISA,	   with	   no	  













Figure	   3.3.	   Samples	   of	   (iii)	   were	   stored	   as	   a	   powder	   (inset	   photo),	   under	   N2	   at	  
temperatures	  up	  to	  57oC	  for	  ~2	  months,	  and	  resolved	  by	  analytical	  HPLC	  to	  determine	  
the	  presence	  of	  any	  degradation	  product.	  	  	  The	  HPLC	  traces	  reveal	  that	  the	  fingerprint	  of	  
the	  PCC	  Agent	   is	  unchanged.	   	  The	   inset	   shows	   that	   the	  assay	  performance	  of	   the	  PCC	  










3.5	  MATERIALS	  AND	  METHODS	  
3.5.1	  Patient	  serum	  ELISA	  
	   Peripheral	  blood	  was	  obtained	  from	  HIV-­‐1	  infected	  patients	  at	  the	  University	  of	  
California,	  Los	  Angeles	   (UCLA)	  Medical	  Center	  between	  July	  and	  August	  of	  2012.	   	  Sera	  
were	   stored	   at	   -­‐80°C	   before	   subsequent	   analysis.	   	   Streptavidin-­‐coated	   96-­‐well	   plates	  
were	  saturated	  with	  the	  biotinylated	  biligand	  cocktail	  or	  chimera	  using	  1	  uM	  solutions	  in	  
TBS.	   	   The	   plates	   were	   blocked	   with	   5%	   w/v	   dry	   milk	   in	   TBS,	   and	   then	   the	   capture	  
reagents	  were	  incubated	  with	  patient	  serum	  samples	  diluted	  to	  1%	  v/v	  in	  TBS	  containing	  
0.1%	  w/v	  bovine	  serum	  albumin	  (BSA).	  	  Additionally,	  both	  cocktail	  and	  chimera	  capture	  
reagents	  were	  incubated	  with	  1%	  v/v	  commercial	  healthy	  human	  serum	  in	  TBS.	  	  Bound	  
antibody	  was	  probed	  with	  HRP-­‐conjugated	  mouse	  monoclonal	  antibody	   to	  human	   IgG	  
Fc,	  diluted	  1:10,000	   in	  TBS	  with	  0.1%	  w/v	  BSA.	   	  The	  colorimetric	  assay	  was	  developed	  
with	  TMB	  substrate,	   then	  quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm	  (A450).	   	  The	  
A450	  for	  each	  sample	  is	  normalized	  against	  the	  A450	  for	  the	  healthy	  control,	  to	  yield	  a	  
measurement	  of	  the	  signal-­‐to-­‐noise	  ratio	  of	  the	  assay.	  	  	  
	  
3.5.2	  PATH	  samples	  ELISA	  
	   Serum	  samples	  were	  obtained	  from	  SeraCare,	  through	  PATH	  of	  POC	  diagnostics	  
program	  funded	  by	  the	  Bill	  and	  Melinda	  Gates	  foundation.	  	  Five	  groups	  of	  four	  samples	  
were	   tested,	  where	  each	  group	  contained	  high,	  medium,	  and	   low	  titer	   samples,	  along	  
with	  a	  negative	  sample	  that	  did	  not	  contain	  anti-­‐HIV	  antibodies.	  	  Sera	  were	  stored	  at	  -­‐
80°C	   before	   subsequent	   analysis.	   	   Streptavidin-­‐coated	   96-­‐well	   plates	   were	   saturated	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with	   the	   biotinylated	   biligand	   cocktail	   or	   chimera	   using	   1	   uM	   solutions	   in	   TBS.	   	   The	  
plates	  were	  blocked	  with	  5%	  w/v	  dry	  milk	   in	  TBS,	  and	  then	  the	  capture	  reagents	  were	  
incubated	   with	   patient	   serum	   samples	   diluted	   to	   1%	   v/v	   in	   TBS	   containing	   0.1%	  w/v	  
bovine	  serum	  albumin	  (BSA).	  	  Additionally,	  both	  cocktail	  and	  chimera	  capture	  reagents	  
were	  incubated	  with	  1%	  v/v	  commercial	  healthy	  human	  serum	  in	  TBS.	  	  Bound	  antibody	  
was	  probed	  with	  HRP-­‐conjugated	  mouse	  monoclonal	  antibody	  to	  human	  IgG	  Fc,	  diluted	  
1:10,000	   in	  TBS	  with	  0.1%	  w/v	  BSA.	   	   The	   colorimetric	   assay	  was	  developed	  with	  TMB	  
substrate,	  then	  quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm	  (A450).	  	  The	  A450	  for	  the	  
samples	  in	  each	  group	  are	  normalized	  against	  the	  A450	  for	  the	  negative	  sample	  in	  that	  
group.	  
	  
3.5.3	  Stability	  assay	  
	   Small	  amounts	  of	   (iii)	  were	  stored	  under	  N2	  at	  25°C,	  37°C,	  or	  57°C	  for	  58	  days.	  	  
Samples	   were	   diluted	   in	   1:1	   ACN/H2O	   with	   0.1%	   v/v	   TFA	   to	   an	   equal	   concentration	  
determined	   by	   measuring	   the	   absorbance	   values	   at	   280	   nm	   using	   NanoDrop	  
spectrophotometer	   (Thermo	   Scientific,	   Waltham,	   MA)	   and	   resolved	   by	   analytical	   RP-­‐
HPLC.	   	   	   The	   remaining	   samples	  were	   lyophilized	   and	   used	   in	   a	   single	   point	   sandwich	  
ELISA.	   	   Streptavidin-­‐coated	   96-­‐well	   plates	   were	   saturated	   with	   the	   samples	   of	   (iii)	  
recovered	  from	  the	  storage	  experiments	  using	  1	  uM	  solutions	  in	  TBS.	  	  The	  plates	  were	  
blocked	  with	  5%	  w/v	  dry	  milk	  in	  TBS,	  then	  incubated	  with	  either	  	  1%	  v/v	  human	  serum	  
or	   10	   nM	   4B3	   spiked	   in	   1%	   v/v	   human	   serum	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   at	   room	  
temperature	   for	   1	   hr.	   	   Bound	   antibody	   was	   probed	   with	   HRP-­‐conjugated	   mouse	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monoclonal	  antibody	  to	  human	  IgG	  Fc	  diluted	  1:15,000	  in	  0.5%	  w/v	  dry	  milk	  in	  TBS.	  	  The	  
colorimetric	  assay	  was	  developed	  with	  TMB	  substrate,	  then	  quenched	  with	  1	  M	  H2SO4	  
and	  read	  at	  450	  nm.	  
	  
3.6	  CONCLUSION	  
	   This	  thesis	  demonstrated	  the	  successful	  application	  of	  this	  method	  for	  HIV-­‐1	  
diagnostics	  by	  producing	  a	  cocktail	  of	  three	  PCC	  Agents	  that	  detected	  the	  presence	  of	  
anti-­‐HIV	  antibodies	  in	  clinical	  samples	  with	  a	  significantly	  enhanced	  signal-­‐to-­‐noise	  
relative	  to	  the	  standard,	  recombinant	  protein-­‐based	  chimeric	  antigen.	  	  In	  a	  recent	  
report,	  an	  antigenic	  peptide	  cocktail	  comprised	  of	  synthetic	  peptides	  derived	  directly	  
from	  gp120/V3-­‐I	  (HIV-­‐1	  Indian	  isolate),	  gp41	  (HIV-­‐1),	  and	  gp36	  (HIV-­‐2),	  as	  well	  as	  the	  
recombinant	  protein	  rp24	  (HIV-­‐1)	  was	  shown	  to	  also	  provide	  superior	  performance	  
relative	  to	  the	  chimeric	  antigen	  [5].	  	  This	  points	  to	  the	  possibility	  that	  expanding	  the	  
current	  approach	  by	  developing	  multiple	  cocktails	  of	  PCC	  Agents,	  each	  directed	  against	  
a	  distinct	  HIV	  epitope,	  would	  likely	  provide	  superior	  performance	  to	  that	  reported	  here.	  
The	  strategy	  presented	  provides	  a	  promising	  approach	  for	  developing	  assays	  for	  
detecting	  the	  immune	  response	  to	  other	  infectious	  agents,	  especially	  where	  challenges	  
associated	  with	  the	  polyclonal	  nature	  of	  a	  humoral	  immune	  response	  can	  compromise	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   This	  chapter	  discusses	  selective	  polarization	  transfer	  from	  15N	  to	  methyl	  1H	  spins	  
in	   15N-­‐choline.	   	   The	   sensitivity	   and	   information	   content	   of	   heteronuclear	   nuclear	  
magnetic	  resonance	  is	  frequently	  optimized	  by	  transferring	  spin	  order	  of	  spectroscopic	  
interest	  to	  the	  isotope	  of	  highest	  detection	  sensitivity	  prior	  to	  observation.	  	  This	  strategy	  
was	  extended	  to	  15N-­‐choline	  using	  the	  scalar	  couplings	  to	  transfer	  polarization	  from	  15N	  
to	  choline’s	  nine	  methyl	  1H	  spins	  in	  high	  field.	  	  A	  theoretical	  analysis	  of	  a	  sequence	  using	  
nonselective	  pulses	  showed	  that	  the	  optimal	  efficiency	  of	  this	  transfer	   is	  decreased	  by	  
62%	   as	   the	   result	   of	   competing	   15N-­‐1H	   couplings	   involving	   choline’s	   four	   methylene	  
protons.	   	  A	   frequency-­‐selective	  pulse	  was	  therefore	   incorporated	  to	  support	  evolution	  
of	  only	  the	  15N-­‐methyl	  1H	  coupling	  during	  the	  transfer	  period.	  	  This	  sequence	  provided	  a	  
52%	  sensitivity	  enhancement	  over	  the	  nonselective	  version	  in	  in	  vitro	  experiments	  on	  a	  
sample	  of	  t	  hermally	  polarized	  15N-­‐choline	  in	  D2O.	  	  Further,	  the	  15N	   1T of	  choline	  in	  D2O	  
was	  measured	  to	  be	   217 38± 	  s,	   the	   15N-­‐methyl	   1H	  coupling	  constant	  was	   found	  to	  be	  
0.817 0.001± 	  Hz,	  and	   the	   larger	  of	  choline’s	   two	  15N-­‐methylene	   1H	  coupling	  constants	  
was	   found	   to	   be	   3.64 0.01± 	  Hz.	   	   Possible	   improvements	   and	   applications	   to	   in	   vivo	  









	   It	   is	   now	  possible	   to	   routinely	   generate	   samples	   of	   certain	   small	   biomolecules	  
with	  nuclear	  polarizations	  on	  the	  order	  of	  ten	  percent	  using	  PASADENA	  (parahydrogen	  
and	   synthesis	   allow	   dramatically	   enhanced	   nuclear	   alignment)	   [1]	   or	   DNP	   (dynamic	  
nuclear	  polarization)	   [2;	   3].	   	   These	   technologies	   show	  promise	   for	   clinical	   applications	  
based	  on	  the	  in	  vivo	  characterization	  of	  metabolic	  processes	  on	  the	  seconds	  timescale.	  	  
Experiments	  of	  this	  nature,	  rely	  on	  storage	  of	  the	  polarization	  on	  heteronuclei	  with	  long	  
population	  	  relaxation	  times,	  such	  as	  carbonyl	  13C	  or	  quaternary	  15N	  nuclei,	   in	  order	  to	  
minimize	   relaxation	   losses	   during	   sample	   delivery	   and	   to	   provide	   time	   for	   transport,	  
binding,	   and	   metabolism.	   	   However,	   the	   sensitivity	   enhancement	   afforded	   by	   this	  
strategy	   is	   partly	   lost	   if	   the	   final	   signal	   is	   also	   detected	   on	   a	   low-­‐𝛾	   heteronucleus.	  
Chekmenev	  et	  al.	  [4]	  have	  proposed	  that	  optimal	  sensitivity	  can	  be	  obtained	  by	  storing	  
polarization	   on	   a	   slowly-­‐relaxing	   heteronuclear	   spin	   and	   then	   using	   an	   INEPT[5]	  
sequence	   to	   coherently	   transfer	  magnetization	   to	   nearby	   1H	  nuclei	   for	   detection,	   and	  
have	  demonstrated	  the	  method	  with	  two	  	  hyperpolarized	  reagents,	   	  1-­‐13C-­‐succinate-­‐d2	  
and	   2,2,3,3-­‐tetrafluoropropyl	   1-­‐13C-­‐propionate-­‐d3	   (TFPP).	   	   Those	   experiments	   were	  
designed	  assuming	  that	  the	  relevant	  1H	  and	  13C	  sites	  were	  3-­‐spin	  ABX	  systems.	  
Here	   we	   demonstrate	   an	   extension	   of	   this	   polarization	   transfer	   strategy	   to	  
hyperpolarized	  15N-­‐choline,	  an	  A9BB’CC’X	  system	  of	  14	  spin	  ½	  nuclei.	  	  Choline	  is	  a	  useful	  
biomarker,	  showing	  significantly	  altered	  uptake	  and	  metabolism	  in	  diseased	  brain	  tissue	  
[6]	  and	  in	  malignant	  tumor	  cells	  in	  the	  breast	  and	  prostate	  [7;	  8].	  	  Hyperpolarization	  of	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15N-­‐choline	  to	   (4.6 1)%± 	  has	  been	  reported	  after	  two	  hours	  of	  DNP	  at	  1.4	  K	  [3].	  	  The	  15N	  
longitudinal	  relaxation	  time	  of	   1 120T = 	  s	  in	  blood	  [3]	  is	  promising	  for	  metabolic	  studies.	  
We	   have	   investigated	   two	   INEPT-­‐based	   pulse	   sequences	   for	   15N-­‐to-­‐1H	  
polarization	   transfer	   in	   15N-­‐choline.	   	   The	   first	   is	   a	   nonselective	   refocused	   INEPT	  
sequence	  similar	  to	  that	  used	  by	  Chekmenev	  et	  al.	  to	  transfer	  polarization	  from	  13C	  to	  
multiple	  1H	  sites	  in	  succinate	  and	  TFPP	  [4].	   	  While	  this	  sequence	  is	  effective,	  a	  product	  
operator	  analysis	  shows	  that	  significantly	  greater	  sensitivity	  can	  be	  obtained	  by	  using	  a	  
selective	  sequence	  targeting	  choline’s	  nine	  degenerate	  methyl	  1H	  spins.	   	  We	  therefore	  
also	  present	  a	  selective	  refocused	  INEPT	  transfer	  that	  uses	  a	  REBURP	  pulse	  to	  support	  
coherence	  transfer	   from	  15N	  to	  choline’s	  methyl	   1H	  spins	  while	  suppressing	  competing	  
transfer	  pathways	   to	  methylene	   1H	  nuclei.	   	   These	  pulse	   sequences	  are	  experimentally	  




	   At	  a	  given	  spin	  polarization	  and	  probe	  efficiency,	   the	  sensitivity	  of	  detection	   in	  
an	  NMR	  experiment	  scales	  as	  the	  square	  of	  the	  gyromagnetic	  ratio	  of	  the	  nuclide	  being	  




( / ) 97γ γ = 	  can	  be	  obtained	  by	  transferring	  to	  1H	  for	  detection	  rather	  than	  directly	  
observing	  a	  15N	  signal,	  assuming	  unity	  transfer	  of	  spin	  angular	  momentum,	  as	  is	  closely	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approached	  within	  an	  isolated	  15N-­‐1H	  spin	  pair	  with	  a	  resolved	  scalar	  coupling.	   	  Such	  a	  
transfer	   can	   be	   achieved	   using	   refocused	   INEPT	   (Figure	   4.1),	   the	   standard	   pulse	  
sequence	   for	   polarization	   transfer	   between	   spins	   with	   a	   direct	   scalar	   coupling.	   	   The	  
effect	  of	  this	  sequence	  when	  applied	  to	  15N-­‐choline	  can	  be	  determined	  using	  a	  product	  
operator	   analysis.	   	   In	   the	   following	   discussion	   the	   relevant	   15N-­‐1H	   scalar	   coupling	  
constants	  will	  be	  labeled	   mJ ,	   aJ ,	  and	   bJ 	  as	  indicated	  in	  Figure	  4.2.	  	  Couplings	  between	  



















Figure	  4.1.	  A	  refocused	  INEPT	  pulse	  sequence	  for	  polarization	  transfer	  from	  15N	  to	  1H	  for	  





























First,	  consider	  the	  effect	  of	  the	  sequence	  on	  the	  spin	  system	  of	  Figure	  4.2,	  while	  
initially	   neglecting	   the	   effects	   of	   the	   15N-­‐methylene	   1H	   couplings	   aJ 	   and	   bJ .	   	   The	  
system’s	   magnetization	   is	   proportional	   to	   the	   dimensionless	   15N	   spin	   angular	  
momentum,	  with	  initial	  value	  normalized	  to	   0 zSρ = .	  	  This	  is	  converted	  to	  in-­‐phase	  
15N	  
single-­‐quantum	   coherence	   by	   the	   first	   15N	   (𝜋/2)x	   pulse	   to	   obtain 1 ySρ = − .	   	   This	  
coherence	  evolves	  under	   the	   15N-­‐methyl	   1H	  scalar	  couplings	  during	   the	   INEPT	   transfer	  
period	   1τ 	  to	  produce	  terms	  that	  are	  antiphase	  with	  respect	  to	  the	  methyl	  
1H	  spins.	  	  The	  
simultaneous	  𝜋	  pulses	  in	  the	  middle	  of	   1τ 	  refocus	  chemical	  shift	  evolution,	  leaving	  only	  
the	  effects	  of	  couplings	  between	  15N	  and	  each	  of	  the	  nine	  methyl	  1H	  spins.	  	  At	  the	  end	  of	  
1τ 	  the	  system’s	  state	  is	  given	  by:	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Here,	  HO	  indicates	  higher-­‐order	  terms,	  specifically	  single-­‐quantum	  15N	  coherence	  that	  is	  
antiphase	  with	  respect	  to	  three	  or	  more	  1H	  spins.	  	  After	  the	  transfer	  delay,	  simultaneous	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The	  pulses	   convert	   the	   terms	   HO 	   to	  high-­‐order	  multiple-­‐quantum	  coherences,	  which	  
have	  been	  abbreviated	  as	   HQ .	  	  At	  this	  point,	  15N	  coherences	  and	  multiple-­‐quantum	  1H	  
coherences,	  which	  will	  not	  lead	  to	  observable	  signals	  at	  the	  end	  of	  the	  experiment,	  can	  
be	  dropped	  from	  the	  density	  operator.	  	  This	  leaves	  only	  single-­‐quantum	  1H	  coherences	  





2 cos ( )sin( )z iy m m
i
S I J Jρ π τ π τ
=
=∑ .	  
The	  next	   part	   of	   the	   sequence	   is	   a	   refocusing	  period	  of	   duration	   2 1/ (2 )mJτ = 	   during	  





cos ( )sin( )ix m m
i
I J Jρ π τ π τ
=
= −∑ .	  
The	   detected	   1H	   signal	   is	   proportional	   to	   the	   total	   magnetization	   of	   the	   nine	  methyl	  
protons,	  so	  the	  dependence	  of	  the	  initial	  signal	  amplitude	  on	   1τ 	  is:	  
	   1 1
89 ( ) ( )sel sel m mJS A cos sin CJπ τ π τ= + .	   (1)	  
This	   expression	   includes	   a	   hardware-­‐dependent	   proportionality	   constant	   selA 	   and	   a	  
constant	  C 	  accounting	  for	  any	  DC	  offset	  in	  the	  observed	  signal.	  	  Equation	  1	  is	  similar	  to	  
the	   expression	   derived	   by	   Doddrell	   et	   al.	   for	   a	   coherence	   transfer	   in	   the	   opposite	  
direction,	   from	   n	   equivalent	   1H	   spins	   to	   a	   heteronucleus	   [9].	   	   The	   value	   of	   1τ 	   that	  









− ⎛ ⎞= ⎜ ⎟
⎝ ⎠
.	  
For	   the	   value	   0.82mJ = 	  Hz	   measured	   experimentally	   for	  
15N-­‐choline,	   the	   optimal	  
transfer	  delay	   is	   1 0.132τ = 	  s,	  yielding	    Ssel = 1.873 Asel + C .	  The	  transfer	   function	  of	  the	  
angular	  momentum	  from	  15N	  to	  1H	  or	  vice	  versa	  (Eq.	  1)	  can	  exceed	  unity.	  	  The	  conserved	  
quantity	   is	   the	   sum	   of	   the	   squares	   of	   the	   coefficients	   of	   the	   normalized	   product	  
operators	  expressing	  the	  density	  operator.	  	  Contributions	  to	  the	  observable	  signal	  from	  
choline’s	   nine	   methyl	   1H	   spins	   combine	   linearly	   and	   constructively	   at	   the	   optimized	  
value	  of	   1τ .	  
The	   above	   calculation	   is	   readily	   generalized	   to	   include	   the	   effects	   of	   scalar	  
coupling	  between	   the	   15N	  spin	  and	   the	   four	  methylene	  protons	   ( aJ 	   and	   bJ 	   in	  Fig.	  2),	  
yielding	  an	  analogous	  relative	  signal	  function:	  
	   8 21 1
2
1 19 ( ) ( ) ( ) ( )m m aon on bn nS A cos sin cos cos CJ J J Jπ τ π τ π τ π τ= + 	   (2)	  
A	   proportionality	   constant nonA and	   a	   DC	   offset	   constant	   C	   have	   again	   been	   included.	  	  
Maximizing	   this	   function	  numerically	   for	   the	   best	   known	   values	   of	   the	   three	   coupling	  
constants	   for	   choline,	   0.82mJ = 	  Hz,	   0.57aJ = − 	  Hz,	   3.64bJ = 	  Hz,	   gives	   an	   optimal	  
transfer	  delay	   1 0.233τ = 	  s,	  which	  yields	  a	  signal	  of	   0.721non nonS A C= + .	  
Comparing	   the	  maximum	   values	   of	   selS 	   and	   nonS ,	   it	   is	   apparent	   that	   the	  
15N-­‐
methylene	  1H	  couplings	  have	  the	  effect	  of	  reducing	  the	  observable	  1H	  signal	  by	  62%	  in	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the	  idealized	  case	  of	  an	  experiment	  for	  which	   sel nonA A= 	  and	   0C = .	  It	  would	  clearly	  be	  
advantageous	  to	  suppress	   these	  couplings.	  This	  can	  be	  achieved	  by	  replacing	  the	  1H	  p	  
pulse	   in	   the	  middle	  of	   1τ 	  with	  a	   selective	  pulse	   tailored	   to	   invert	   the	  methyl	  
1H	   spins	  
without	  affecting	  the	  methylene	  1H	  spins.	  
	  
4.4	  EXPERIMENTAL	  
	   Data	   was	   collected	   on	   a	   Varian	   UNITYINOVA	   spectrometer	   operating	   at	   a	   1H	  
resonance	   frequency	  of	  500	  MHz.	   	   The	   sample	  was	  prepared	  by	  dissolving	  20	  mg	   15N-­‐
choline	   chloride	   (ISOTEC,	   Miamisburg,	   Ohio)	   in	   700	  µl	   D2O.	   	   Refocused	   INEPT	  
experiments	   were	   performed	   using	   the	   pulse	   sequence	   shown	   in	   Figure	   4.3,	   which	  
implements	  the	  selective	  15N-­‐methyl	  1H	  transfer	  described	  in	  the	  theory	  section	  using	  a	  
6.695	  ms	   1H	   REBURP	   pulse	   [10]	   centered	   at	   the	   methyl	   1H	   frequency.	   	   A	   time	   rebτ =	  
6.4	  ms,	  equal	   to	   the	  effective	  evolution	   time	  of	   the	   15N-­‐methyl	   1H	  coupling	  during	   the	  
REBURP	   pulse,	   was	   subtracted	   from	   the	   transfer	   delay	   as	   indicated	   in	   Fig.	   3.	   	   For	  
nonselective	  INEPT	  experiments,	  the	  REBURP	  was	  replaced	  with	  a	  nonselective	  𝜋	  pulse	  







Figure	  4.3.	   Selective	   refocused	   INEPT	  pulse	   sequence	   for	   coherent	  polarization	  
transfer	   from	   15N	   to	   methyl	   1H	   in	   15N-­‐choline.	   	   Narrow	   (wide)	   rectangles	   denote	  
radiofrequency	   pulses	   with	   a	   tip	   angle	   of	   𝜋/2	  (𝜋),	   applied	   with	   B1	   field	   strengths	   of	  
23.9	  kHz	   for	   1H	  and	  15.6	  kHz	   for	   15N.	   	  The	  shaped	   1H	  pulse	   is	  a	  6.695	  ms	  REBURP	   [10]	  
centered	  on	  the	  methyl	  1H	  frequency.	  	  A	  four	  step	  phase	  cycle	  (𝜑1	  =	  x,	  x,	  x,	  x;	  𝜑2	  =	  x,	  y,	  x,	  
y;	  𝜑rec	  =	  x,	  y,	  x,	  y)	  was	  used	  to	  suppress	  signals	  originating	  from	  1H	  magnetization	  and	  to	  
prevent	  carry	  over	  of	  signal	  from	  one	  transient	  to	  the	  next.	   	  A	  recycle	  delay	   1d 	  of	  60	  s	  
(~	  0.25	   1T )	  was	  used.	  	  Since	  it	  is	  impractical	  to	  make	  this	  delay	  long	  enough	  to	  allow	  full	  
relaxation	   of	   the	   choline	   15N	   spin,	   a	   purge	   element	   consisting	   of	   a	   15N	   𝜋/2	   pulse	  
sandwiched	  by	  gradients	  g0	  and	  g1	  is	  used	  to	  eliminate	  15N	  magnetization	  at	  the	  start	  of	  
1d ,	   ensuring	   a	   consistent	   starting	   magnetization	   for	   all	   experiments.	   	   A	  
1H	   purge	  
element	  comprising	  a	  1H	  𝜋/2	  pulse	  and	  gradient	  g2	  is	  used	  at	  the	  start	  of	  each	  transient.	  	  
Gradients	   g3	   and	   g4	   are	   used	   to	   suppress	   coherence	   transfer	   pathways	   created	   by	  




To	   allow	   efficient	   testing	   in	   the	   absence	   of	   hyperpolarization,	   the	   sequence	  
includes	   a	   15N	   purge	   element	   before	   the	   recycle	   delay	   1d 	   to	   ensure	   that	   the	   system	  
reaches	   a	   consistent	   state	   at	   the	   start	   of	   each	   transient.	   	   This	   measure	   is	   necessary	  
because	   it	   is	   impractical	   to	   allow	   full	   relaxation	   of	   the	   choline	   15N	   spin	   after	   each	  
transient	  owing	  to	  its	  very	  long	   1T .	  	  The	  sequence	  includes	  a	  
15N	  𝜋/2	  pulse	  immediately	  
prior	   to	   acquisition	   in	   order	   to	   purge	   any	   1H	   coherence	   that	   remains	   antiphase	   with	  
respect	   to	   15N	   after	   the	   refocusing	   period.	   	   In	   the	   absence	   of	   this	   pulse,	   intermittent	  
phase	  aberrations	  were	  observed	  in	  the	  methyl	  1H	  resonance.	  	  
For	  15N	   1T 	  measurements	  by	  inversion-­‐recovery,	  the	  pulse	  sequence	  of	  Figure	  4.3	  
was	  modified	  by	  adding	  a	  15N	  𝜋	  pulse	  and	  a	  variable	  recovery	  delay	  immediately	  before	  
the	   1H	   purge	   pulse.	   	   For	   these	   experiments,	   the	   15N	   purge	   element	   before	   1d 	   was	  
removed	  and	   1d 	  was	  increased	  to	  600	  s.	  
Data	   analysis	   was	   performed	   in	   MATLAB	   (The	   MathWorks,	   Natick,	   MA)	   using	  
scripts	   developed	   in	   house.	   	   Spectral	   data	   was	   quantified	   by	   fitting	   the	   methyl	   1H	  
resonance	   to	   a	   complex	   Lorentzian	   lineshape	   function,	   except	   for	   inversion-­‐recovery	  
data,	  which	  was	  quantified	  by	   integration.	   	  A	  downhill	  simplex	  algorithm	  was	  used	  for	  
least-­‐squares	  data	  fitting,	  and	  uncertainties	  in	  the	  extracted	  parameters	  were	  estimated	  
using	  a	  bootstrap	  Monte	  Carlo	  method	  [11].	  
The	  value	  of	   rebτ ,	  which	  is	  subtracted	  from	  the	  INEPT	  transfer	  delay	  in	  order	  to	  
account	   for	   evolution	   of	   the	   15N-­‐methyl	   1H	   scalar	   coupling	   during	   the	   long	   REBURP	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pulse,	  was	  determined	  using	  a	  numerical	  simulation	  of	  the	  pulse	  sequence.	  	  Calculations	  
were	  performed	  in	  GAMMA	  v4.1.2	  [12]	  in	  Hilbert	  space	  using	  a	  spin	  system	  of	  practical	  
size,	  consisting	  of	  one	  15N	  and	  six	  methyl	  1H	  spins,	  with 0.82mJ = 	  Hz.	  The	  
1H	  resonance	  
frequency	  was	  set	  to	  500	  MHz,	  and	  the	  carrier	  frequencies	  were	  set	  on	  resonance	  with	  
the	  15N	  and	  methyl	  1H	  spins.	   	  The	  REBURP	  and	  the	  nonselective	  pulses	  were	  simulated	  
with	  finite	  widths	  corresponding	  to	  the	  experimental	  values,	  and	  relaxation	  and	  phase	  
cycling	  were	  neglected.	  	  The	  pulse	  sequence	  shown	  in	  Figure	  4.3	  was	  simulated,	  and	  the	  
methyl	   1H	  signal	  amplitude	  was	  calculated,	   for	  each	  of	  a	   series	  of	  values	  of	   the	   INEPT	  
transfer	  delay	   1( )rebτ τ− .	   	   The	   signal	  data,	   shown	   in	  Figure	  4.4,	  was	   then	  subjected	   to	  
least-­‐squares	  fit	  to	  a	  version	  of	  Eq.	  1	  appropriate	  for	  a	  system	  containing	  six	  methyl	  1H	  
spins	  and	  including	   rebτ 	  as	  an	  adjustable	  parameter,	  resulting	  in	  the	  value	  of	   6.4rebτ =











Figure	  4.4.	  Numerical	  simulation	  of	  the	  selective	  15N-­‐to-­‐1H	  INEPT	  pulse	  sequence	  acting	  
on	   a	   simplified	   spin	   system.	   	   Circles	   are	   simulated	   methyl	   1H	   signal	   amplitudes	   for	  
different	  values	  of	  the	  INEPT	  transfer	  delay	   1( )rebτ τ− .	   	  The	  line	  was	  calculated	  using	  a	  
modified	  form	  of	  Eq.	  1	  with	  parameter	  values	  from	  a	  least-­‐squares	  fit	  to	  the	  data.	  	  This	  
fit	   was	   used	   to	   determine	   rebτ ,	   the	   effective	   evolution	   time	   of	   the	  
15N-­‐methyl	   1H	  









4.5	  RESULTS	  AND	  DISSCUSSION	  
Figure	  4.5	  shows	  a	  spectrum	  of	  15N-­‐choline	  recorded	  using	  the	  selective	  15N-­‐to-­‐
1H	  INEPT	  sequence	  of	  Figure	  4.3,	  alongside	  a	  15N-­‐detected	  spectrum	  of	  the	  same	  sample	  
recorded	  in	  a	  similar	  measurement	  time.	  	  It	  is	  not	  meaningful	  to	  compare	  these	  spectra	  
quantitatively	   because	   they	   were	   both	   recorded	   using	   a	   probe	   that	   is	   optimized	   for	  
direct	  heteronuclear	  observation,	  a	  factor	  which	  diminishes	  the	  sensitivity	  advantage	  of	  
1H	  detection.	  	  However,	  even	  under	  these	  unfavorable	  circumstances	  the	  signal-­‐to-­‐noise	  
ratio	  is	  clearly	  much	  higher	  in	  the	  selective	  INEPT	  spectrum	  (Figure	  4.5a)	  than	  in	  the	  15N-­‐
detected	  spectrum	  (Figure	  4.5b).	  	  
A	   modified	   version	   of	   the	   selective	   15N-­‐to-­‐1H	   INEPT	   experiment	   was	   used	   to	  
measure	  the	  15N	  longitudinal	  relaxation	  time	  of	  15N-­‐choline	  in	  D2O	  solution,	  and	  a	  value	  
of	   1 (217 38)T = ± 	  s	   was	   obtained	   (Figure	  4.6).	   	   This	   is	   comparable	   to	   the	   value	  
1 (285 12)T = ± 	  s	   previously	   reported	   by	   Gabellieri	   et	   al.	   [3]	   for	  
15N-­‐choline	   in	   90%	  










Figure	  4.5.	   (a)	  1H	  spectrum	  of	  15N-­‐choline	  recorded	  using	  the	  selective	  15N-­‐to-­‐1H	  INEPT	  
sequence	  of	  Fig.	  3.	  	  Only	  the	  methyl	  resonance	  is	  shown.	  	  (b)	  Single-­‐pulse	  15N	  spectrum	  
of	  15N-­‐choline,	  recorded	  with	  tip	  angle	  𝜋/2.	  	  Spectra	  (a)	  and	  (b)	  were	  each	  collected	  on	  
the	  same	  Varian	  AutoX	  Dual	  Broadband	  probe,	  taking	  the	  sum	  of	  four	  transients	  with	  a	  
recycle	   delay	   of	   60	  s.	   	   An	   enhancement	   factor	   of	   11.0	   greater	   sensitivity	   when	   using	  
selective	  15N-­‐to-­‐1H	  INEPT	  sequence	  was	  estimated	  from	  Monte	  Carlo	  fits	  of	  (a)	  and	  (b)	  to	  
Lorentzian	   lineshapes.	   	   The	  peak	   amplitudes	  were	  used	   as	   “signals”	   and	   the	   standard	  
deviations	  as	  “noise”	  to	  construct	  pseudo	  “SNR”	  values	  for	  each	  spectrum	  to	  take	  into	  













Figure	  4.6.	  Measurement	  of	   the	   15N	   longitudinal	   relaxation	   time	  of	   15N-­‐choline	   in	  D2O	  
solution	   using	   a	   modified	   version	   of	   the	   pulse	   sequence	   shown	   in	   Figure	   3.	   	   The	  
experiment	  was	  repeated	  for	  13	  values	  of	  the	  inversion-­‐recovery	  delay	  T	  =	  0.001,	  15,	  30,	  
45,	   …,	   180	  s.	   	   Crosses	   are	   experimental	   methyl	   1H	   signal	   amplitudes	   obtained	   by	  
integrating	  the	  spectral	  data.	  	  The	  line	  was	  calculated	  using	  the	  indicated	  equation	  and	  









A	   series	   of	   15N-­‐choline	   15N-­‐to-­‐1H	   INEPT	   spectra	   were	   recorded	   using	   both	  
selective	  and	  nonselective	  versions	  of	  the	  pulse	  sequence	  of	  Figure	  3	  with	  values	  of	  the	  
transfer	   delay	   1τ 	   ranging	   from	   6.4	  ms	   to	   700	  ms.	   	   The	   methyl	  
1H	   signal	   amplitudes	  
observed	   in	   these	  experiments	  are	  plotted	   in	   Figure	  7.	   	   The	   selective	   INEPT	   sequence	  
allows	   15N-­‐choline	   to	   be	   detected	   with	   52%	   greater	   sensitivity	   than	   the	   nonselective	  
sequence,	   comparing	   the	   maximum	   signal	   amplitude	   observed	   in	   each	   case.	   	   In	   the	  
Theory	  section,	  the	  amplitude	  of	  the	  methyl	  1H	  signal	  was	  predicted	  as	  a	  function	  of	  the	  
transfer	   delay	   for	   the	   selective	   (Eq.	   1)	   and	   nonselective	   (Eq.	   2)	   experiments	   using	   a	  
product	  operator	  analysis.	  	  By	  fitting	  the	  observed	  signal	  amplitudes	  to	  Eqs.	  1	  and	  2,	  the	  
optimal	  length	  of	   1τ 	  for	  each	  experiment	  can	  be	  determined,	  as	  well	  as	  precise	  values	  of	  
choline’s	  15N-­‐1H	  coupling	  constants.	  	  
A	   simultaneous	   least-­‐squares	   fit	   to	   both	   datasets	   yields	   parameter	   values	  
0.632 0.001selA = ± ,	   1.000 0.005nonA = ± ,	   (0.817 0.001)mJ = ± 	  Hz,	   ( )3.64  0.01  bJ = ± 	  Hz,	  
and	   0.000 0.001C = ± .	   	   These	   values	   for	   the	   coupling	   constants	   agree	  well	  with	   ones	  
derived	   from	   previously	   published	   1H-­‐14N	   values:	   0.80mJ = 	  Hz	   and	   3.61bJ = 	  Hz	   [13].	  	  
The	   value	   of	   the	   smaller	   15N-­‐methylene	   1H	   coupling	   constant	   was	   found	   to	   have	   a	  
negligible	  effect	  on	  the	  fitting	  process,	  so	  this	  parameter	  was	  fixed	  at	  a	  reasonable	  value	  






Figure	  4.7.	  Amplitude	  of	  the	  methyl	  1H	  signal	  observed	  in	  15N-­‐to-­‐1H	  INEPT	  spectra	  of	  15N-­‐
choline	   using	   selective	   (circles)	   and	   nonselective	   (triangles)	   versions	   of	   the	   pulse	  
sequence	   shown	   in	   Figure	  3,	   as	   a	   function	  of	   the	   INEPT	   transfer	   period	   1τ .	   	   The	   lines	  
were	   calculated	  using	  Eq.	   1	   (solid	   line)	   and	  Eq.	   2	   (dashed	   line)	  with	  parameter	   values	  










Note	  that,	   for	  experiments	  using	  the	  selective	  and	  nonselective	  versions	  of	   the	  
pulse	   sequence	   of	   Figure	   3	   on	   the	   same	   spectrometer	   hardware	   and	   sample,	   the	  
constants	  C 	  in	  Eqs.	  1	  and	  2	  should	  be	  the	  same,	  but	   selA 	  may	  be	  smaller	  than	   nonA 	  due	  
to	  signal	  losses	  during	  the	  selective	  sequence’s	  REBURP	  pulse.	  	  Comparing	  the	  values	  of	  
selA 	  and	   nonA 	   from	  the	  least	  squares	  fit	   it	  appears	  that	  36%	  of	  the	  signal	   is	   lost	   in	  this	  
way.	  	  This	  can	  be	  attributed	  in	  part	  to	  miscalibration	  of	  the	  REBURP	  pulse.	  	  A	  three	  pulse	  
sequence	  (𝜋/2	  -­‐	  REBURP	  -­‐	  𝜋/2)	  was	  used	  to	  calibrate	  the	  REBURP	  pulse	  by	  seeking	  pulse	  
width	   and	   power	   parameters	   that	   gave	   the	   best	   null	   signal.	   	   It	   would	   be	   more	  
appropriate	  to	  choose	  a	  calibration	  sequence	  that	  uses	  the	  REBURP	  pulse	  for	  inversion,	  
as	   it	   is	   used	   in	   the	   selective	   INEPT	   sequence,	   rather	   than	   for	   refocusing.	   	   Also,	   a	  
sequence	  with	  a	   larger	  number	  of	  pulses	  would	  be	  preferable,	   so	   that	   the	  cumulative	  
effects	  of	  B1	   inhomogeneity	  would	  be	  comparable	   in	  the	  calibration	  sequence	  and	  the	  
selective	  INEPT	  sequence.	  
We	   have	   presented	   a	   pulse	   sequence	   that	   suppresses	   the	   effects	   of	   the	   four	  
methylene	  protons	  on	   the	   INEPT	   transfer	   from	   15N	   to	  methyl	   1H	   in	   15N-­‐choline.	   	  Note	  
that	   the	   same	   result	   can	   be	   achieved	   by	   selective	   deuteration	   of	   15N-­‐choline.	   	   This	  
approach	   might	   provide	   the	   additional	   benefit	   of	   increasing	   the	   molecule’s	   15N	  
longitudinal	   relaxation	   time	   and	  would	   be	   an	  option	   for	  DNP	  experiments.	   	  However,	  
the	   present	   selective	   recoupling	   strategy	   is	   clearly	   advantageous	   for	   15N-­‐choline	  
hyperpolarization	   using	   PASADENA.	   	   In	   these	   experiments,	   two	   of	   the	   methylene	   1H	  
spins	  derive	  from	  a	  parahydrogen	  molecule	  which	  reacts	  with	  an	  unsaturated	  precursor	  
to	  initiate	  the	  hyperpolarization	  process.	  	  Although	  deuteration	  of	  the	  alkene	  precursor	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can	  remove	  two	  of	  the	  methylene	  1H	  spins,	  those	  which	  supply	  the	  spin	  order	  cannot	  be	  
eliminated.	  
The	  success	  of	  this	  selective	  coherence	  transfer	  strategy	  in	  15N-­‐choline	  has	  clear	  
implications	   for	   studies	   of	   other	   hyperpolarized	   small	   biomolecules.	   	   By	   directing	   the	  
spin	   order	   to	   a	   subset	   of	   the	   possible	   detection	   spins,	   sensitivity	   is	   improved.	   	   The	  
recoupling	   strategy	   demonstrated	   here	   accomplishes	   this	   by	   way	   of	   a	   frequency	  
selective	  π	   pulse,	  which	   simplifies,	   and	   often	   shortens,	   the	   polarization	   transfer	   step.	  	  
Similar	  selective	  INEPT	  sequences	  could	  be	  used	  to	  improve	  the	  sensitivity	  of	  the	  13C-­‐to-­‐
1H	   polarization	   transfer	   experiments	   demonstrated	   by	   Chekmenev	   et	   al.	   in	  
hyperpolarized	  TFPP	  [4]	  by	  directing	  the	  spin	  order	  to	  one	  of	  the	  resolved	  1H	  sites.	  
The	   selective	   15N-­‐choline	   transfer	   presented	   here	   also	   has	   potentially	   useful	  
applications	   to	   thermally	   polarized	   in	   vivo	   15N	   spectroscopy.	   	   Pulse	   sequences	   can	   be	  
devised	  to	  transfer	  methyl	  1H	  polarization	  to	  15N	  for	  an	  encoding	  period	  and	  then	  back	  
to	  methyl	   1H	   for	  detection.	   	   Such	   sequences	  would	  benefit	   from	  choline’s	   long	   15N	   1T 	  
while	  making	  use	  of	   the	  strong	  thermal	  polarization	  of	   the	  nine	  methyl	   1H	  spins.	   	  This	  
strategy	  could	  be	  used	  to	  resolve	  species	  such	  as	  choline	  and	  phosphocholine	  by	  15N-­‐1H	  
correlation	  spectroscopy,	  or	  even	  to	  study	  the	  metabolic	  interconversion	  of	  choline	  and	  






As	  part	  of	  a	  strategy	  to	  improve	  the	  sensivity	  of	   in	  vivo	  experiments	  on	  hyperpolarized	  
small	   biomolecules,	   we	   have	   investigated	   INEPT	   pulse	   sequences	   for	   the	   transfer	   of	  
magnetization	  from	  15N	  to	  the	  methyl	  1H	  spins	  in	  15N-­‐choline.	  	  Product	  operator	  analysis	  
of	   a	   simple	   refocused	   INEPT	   sequence	   shows	   that	   the	   optimized	   efficiency	   of	   this	  
transfer	   is	   diminished	  by	   62%	  by	   the	   action	   of	   competing	   couplings	   between	   15N	   and	  
choline’s	  methylene	  1H	  spins.	  	  A	  selective	  INEPT	  sequence,	  using	  a	  1H	  REBURP	  pulse	  to	  
suppress	  undesired	  couplings	  during	  the	  transfer	  period,	  was	  devised	  and	  tested	  in	  vitro	  
on	   a	   thermally	   polarized	   15N-­‐choline	   sample.	   	   It	   was	   demonstrated	   that	   the	   selective	  
INEPT	  sequence	  leads	  to	  a	  52%	  stronger	  methyl	  1H	  signal	  than	  the	  nonselective	  version.	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Understanding	  PCC	  Agent	  Binding	  to	  Single	  Point	  Mutation	  E17K	  of	  Akt1	  Pleckstrin	  











	   The	  Akt	  kinase	  is	  a	  critical	  molecular	  router	  that	  mediates	  cell	  growth,	  apoptosis,	  
and	  translation	  [1],	  and	  Akt	  overexpression	  and/or	  hyperactivation	  has	  been	  observed	  in	  
many	  cancer	  types	  [2].	  	  The	  Akt1	  activation	  mechanism	  includes	  binding	  to	  the	  PIP3	  lipid	  
on	   the	   cell	   membrane	   with	   a	   domain	   called	   the	   Pleckstrin	   Homology	   Domain	   (PHD).	  	  
Mutations	   in	  the	  PHD	  of	  Akt1	  that	   increase	   its	  affinity	   for	  binding	  with	  PIP3	  will	  cause	  
the	   upregulation	   of	   downstream	   pathways,	   thereby	   promoting	   the	   formation	   of	  
cancerous	  cells	  [3].	  
	   Recent	  experiments	  performed	  on	  mice	  have	  revealed	  that	  a	  single	  amino	  acid	  
point	  mutation	   to	   the	  PHD	  of	  Akt1,	   called	   the	  E17K	  mutation,	  was	   sufficient	   to	   cause	  
cancer	  [4].	  	  This	  same	  mutation	  has	  been	  found	  in	  certain	  human	  ovarian,	  colorectal	  and	  
breast	   cancers.	   	   The	   E17K	   mutation	   exchanges	   a	   negatively	   charged	   glutamate	   for	   a	  
positively	   charged	   lysine,	   causing	   the	   formation	   of	   an	   additional	   hydrogen	   bond	  
between	   the	   PHD	   and	   PIP3	   on	   the	   cell	   membrane.	   	   This	   induces	   a	   conformational	  
change	   that	   causes	   Akt1(E17K)	   to	   bind	   to	   the	   plasma	  membrane	   four	   times	   stronger	  
than	  it	  would	  in	  its	  wild-­‐type	  form	  [4].	  	  This	  strengthened	  binding	  is	  believed	  to	  be	  the	  
underlying	  mechanism	  for	  the	  creation	  of	  a	  type	  of	  cancerous	  cells	  in	  mice.	  
	   It	  is	  hypothesized	  that	  blocking	  the	  binding	  between	  PIP3	  and	  Akt1(E17K)	  could	  
reduce	  or	   terminate	   the	  growth	  of	  cancerous	  cells	  derived	   from	  the	  E17K	  mutation	   in	  
humans,	  thus	  serving	  as	  a	  less	  invasive	  and	  less	  toxic	  means	  of	  chemotherapy.	  	  Previous	  
work	  has	  shown	  that	  peptide	  capture	  agents	  can	  be	  raised	  against	  Akt	  that	  are	  epitope	  
targeted	  and/or	  inhibitory	  [5,6,7].	  	  Specifically,	  a	  5mer	  peptide	  capture	  agent	  (yleaf)	  has	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been	  developed	  to	  bind	  to	  the	  E17K	  mutation	  of	  the	  PH	  domain	  of	  Akt1	  [7].	  	  Molecular	  
dynamics	   (MD)	   trajectories	   of	   the	   peptide/protein	   complex	   are	   constructed	   for	   the	  
anchor	   with	   both	   the	   mutant	   and	   wild	   type	   (WT)	   Akt1	   PH	   domains,	   and	   used	   to	  
calculate	  the	  free	  energy	  of	  binding	  for	  each	  system.	  
	  
A.2	  PEPTIDE	  CAPTURE	  AGENT	  AGAINST	  E17K	  MUTATION	  OF	  AKT1	  PHD	  
	   Work	  in	  the	  Heath	  group	  has	  yielded	  a	  5mer	  anchor	  peptide	  that	  differentiates	  
the	  E17K	  mutated	  Akt1	  PHD	  from	  the	  wild	  type	  domain	  [7].	  	  The	  epitope	  targeted	  one-­‐
bead-­‐one-­‐compound	  screening	  method	  used	  to	   identify	   the	   ligand	  provides	  an	  anchor	  
point	   for	   the	   C-­‐terminus	   location	   of	   peptide	   binding.	   	   Additionally,	   biotin	   labeling	  
experiments	  done	  using	  a	  variant	  of	  the	  peptide	  with	  an	  N-­‐terminal	  tosyl-­‐biotin	  labeling	  
arm	  indicate	  a	  general	  region	  of	  N-­‐terminal	  peptide	  interaction	  with	  the	  target	  around	  
the	  residue	  Y26	   [8].	   	  These	  data	  were	  used	   in	  choosing	   the	   initial	  configuration	  of	   the	  
yleaf-­‐tosyl-­‐biotin	  ligand	  in	  relation	  to	  either	  the	  E17K	  or	  WT	  target.	  
	  
A.3	  CONSTRUCTION	  OF	  E17K	  AND	  WT	  SYSTEMS	  
A.3.1	  yleaf-­‐tosyl-­‐biotin	  
	   The	   N-­‐terminal	   tosyl-­‐biotin	   labeling	   arm	   was	   constructed	   in	   ChemDraw,	   then	  
imported	   into	   Maestro.	   	   The	   bond	   lengths	   were	   manually	   doubled,	   and	   then	   the	  
B3LYP/6-­‐31G**	  optimized	  structure	  and	  Mulliken	  charges	  were	  obtained	  using	   Jaguar.	  	  
Unknown	   bond	   length,	   bond	   angle,	   and	   torsion	   parameters	   for	   the	   tosyl	   group	  were	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optimized	   using	   B3LYP/6-­‐31G**	   in	   Jaguar.	   	   The	   yleaf	   peptide	   was	   grown	   onto	   the	  
minimized	   tosyl	   structure	   using	   (D)	   amino	   acids	   to	   form	   the	   complete	   ligand.	   	   yleaf-­‐
tosyl-­‐biotin	   was	   equilibrated	   in	   explicit	   water	   at	   300	   K	   for	   1	   ns	   to	   obtain	   the	   ligand	  
conformation	  (Figure	  A.1)	  used	  to	  construct	  the	  ligand/protein	  complexes.	  
	  
A.3.2	  Ligand/Protein	  Complexes	  
	   Crystal	  structures	  for	  E17K	  (2UZR)	  and	  wild	  type	  (1UNP)	  Akt1	  PH	  domains	  were	  
obtained	  from	  the	  Protein	  Data	  Bank.	  	  ZDOCK	  was	  used	  to	  determine	  an	  initial	  relative	  
configuration	  of	   the	   ligand	  shown	   in	  Figure	  A.1	  to	  the	  E17K	  PHD.	   	  The	  anchor	  peptide	  
was	  initially	  screened	  against	  the	  32mer	  fragment	  corresponding	  to	  residues	  1-­‐32	  of	  the	  
E17K	  PHD,	  and	  ZDOCK	  predictions	  were	  restricted	  to	  only	  include	  relative	  conformations	  
that	   allowed	   for	   interaction	   of	   the	   ligand	   with	   this	   fragment.	   	   The	   selected	   ligand	  
configuration	  was	   also	   used	   for	   the	  wild	   type	   PH	   domain.	   	   Figure	   A.2	   shows	   the	   top	  
three	   ZDOCK	   output	   structures,	   and	   Figure	   A.3	   shows	   the	   chosen	   structure	   for	   both	  
E17K	  and	  WT	  systems.	  	  







Figure	  A.1.	  A.	  ChemBioDraw	  structure	  of	  yleaf-­‐tosyl-­‐biotin.	  	  B.	  Equilibrated	  structure	  of	  











Figure	   A.2.	   Top	   three	   ZDOCK	   predicted	   conformations	   of	   yleaf-­‐tosyl-­‐biotin/E17K	   PH	  
domain	  complex.	  	  Interaction	  was	  constrained	  to	  occur	  only	  with	  the	  first	  32	  residues	  of	  
the	  protein	  (highlighted)	  that	  represent	  the	  fragment	  against	  which	  the	  peptide	   ligand	  
was	  raised.	  	  The	  two	  amino	  acids	  of	  interest	  from	  experimental	  binding	  assays,	  E17K	  and	  






Figure	   A.3.	   Selected	   ligand	   conformation	   complexed	  with	   the	  mutant	   (blue)	   and	  wild	  
type	   (purple)	  PH	  domains.	   	  This	  structure	  was	  chosen	  because	  the	   ligand	  most	  closely	  











A.4	  MOLECULAR	  DYNAMICS	  
	   The	  systems	  were	  neutralized	  by	  adding	  Cl−	  or	  Na+	  counterions	  as	  necessary,	  and	  
were	   fully	   solvated	   in	   TIP3P	   water	   boxes.	   	   Each	   system	   was	   first	   subjected	   to	   a	  
minimization	  of	  10,000	  steps.	  	  Then	  the	  solvent	  molecules,	  ligand,	  and	  binding	  fragment	  
were	   equilibrated	   for	   200	   ps	   at	   300	   K	   while	   the	   remaining	   protein	   coordinates	   were	  
fixed.	  	  The	  full	  systems	  were	  then	  minimized	  for	  5,000	  steps.	  	  Finally,	  both	  systems	  were	  
equilibrated	  for	  a	  total	  of	  5	  ns	  at	  300	  K.	  The	  MD	  simulations	  were	  carried	  out	  with	  the	  
NAMD	  2.6	  program	  [9].	  	  Plots	  of	  the	  root	  mean	  squared	  deviation	  (rmsd)	  from	  the	  initial	  
configuration	  of	  the	  trajectories	  and	  restarted	  trajectories	  from	  both	  systems	  are	  shown	  













Figure	  A.4.	  Rmsd	  plots	  for	  the	  MD	  trajectories	  and	  restarted	  trajectories	  of	  the	  E17K	  and	  






A.5	  BINDING	  ENERGY	  
	   To	  obtain	  a	  good	  comparison	  of	  free	  binding	  energy	  between	  the	  two	  systems,	  
energy	   landscapes	  were	   constructed	   for	   E17K	   and	  WT	   by	   plotting	   the	   free	   energy	   of	  
binding	  of	  conformations	  representing	  local	  macrostates	  vs.	  their	  rmsd	  from	  the	  lowest	  
energy	  conformation,	  similar	  to	  the	  approach	  taken	  by	  [10].	  	  If	  the	  reference	  structure	  is	  
truly	   the	   lowest	  energy,	   the	   landscape	  will	   be	   smoothly	   funnel	   shaped.	   	   If	   there	   is	   an	  
alternative	   lowest	   energy	   structure,	   the	   landscape	  will	   be	   non-­‐funnel	   shaped.	   	   Figure	  
A.5	   shows	   examples	   of	   this	   type	   of	   landscape,	   where	   each	   dot	   represents	   one	   of	  
200,000–400,000	   independent	   Rosetta	  ab	  initio	  structure	   prediction	   simulations	   [10].	  	  
For	   the	   purpose	   of	   this	  work,	   the	   rmsd	   of	   each	   trajectory	   is	   like	   a	   partition	   function,	  
where	  each	  point	  represents	  a	  microstate.	  	  Plateaus	  in	  the	  rmsd	  represent	  macrostates,	  
and	   given	   an	   infinite	   amount	   of	   simulation	   time,	   the	   system	  will	   spend	   a	   Boltzmann	  
weighted	  percentage	  of	  time	  in	  each	  macrostate.	  	  Binding	  energies	  were	  calculated	  for	  a	  
number	  of	  100	  ps	  plateaus	  in	  each	  trajectory	  using	  a	  Generalized	  Born	  implicit	  solvent	  
model.	   	   After	   identifying	   the	   conformation	  with	   the	   lowest	   calculated	   binding	   energy	  
REF,	   the	   energies	   of	   the	  other	   conformations	  were	  plotted	   against	   the	   rmsd	  of	   those	  
conformations	  relative	  to	  REF.	   	  The	  energy	  vs.	  rmsd	  plot	  for	  the	  E17K	  and	  WT	  systems	  
are	  shown	  in	  Figures	  A.6	  and	  A.7,	  and	  the	  structure	  of	  the	  chosen	  reference	  structures	  
are	  shown	  in	  Figure	  A.8.	   	  Significantly	  fewer	  data	  points	  were	  able	  to	  obtained	  for	  the	  
E17K	  and	  WT	  systems	  than	  the	  ab	  initio	  structure	  prediction	  simulations,	  but	  the	  plots	  
suggest	   the	   funnel	   shape	   described	   by	   [10],	   indicating	   that	   the	   correct	   lowest	   energy	  




Figure	   A.5.	   Energy	   landscapes	   obtained	   from	   Rosetta	  ab	  initio	  structure	   prediction	  
simulations	   on	   Rosetta@home.	   Red	   points	   represent	   the	   lowest-­‐energy	   structures	  
obtained	  in	  independent	  Monte	  Carlo	  structure	  prediction	  trajectories	  starting	  from	  an	  
extended	   chain	   for	   each	   sequence;	   the	  y	  axis	   shows	   the	   Rosetta	   all-­‐atom	   energy	   and	  
the	  x	  axis	   shows	   the	   Cα	  root	   mean	   squared	   deviation	   from	   the	   design	   model.	   Green	  
points	  represent	  the	  lowest-­‐energy	  structures	  obtained	  in	  trajectories	  starting	  from	  the	  
design	  model.	  	  The	  bottom	  figure	  shows	  a	  landscape	  that	  is	  funnel	  shaped,	  and	  the	  top	  








Figure	   A.6.	   Energy	   landscape	   for	   E17K	   complex.	   	   The	   y-­‐axis	   is	   the	   Generalized	   Born	  
calculation	  of	  binding	  energy,	  and	   the	  x-­‐axis	   is	   the	   rmsd	   relative	   to	   the	   lowest	  energy	  
structure.	   	  Each	  point	  is	  a	  plateau	  in	  the	  trajectory	  rmsd,	  representing	  a	  macrostate	  of	  
the	   system.	   	   The	   binding	   energy	   of	   the	   reference	   state	   calculated	   without	   including	  










Figure	   A.7.	   Energy	   landscape	   for	   WT	   complex.	   	   The	   y-­‐axis	   is	   the	   Generalized	   Born	  
calculation	  of	  binding	  energy,	  and	   the	  x-­‐axis	   is	   the	   rmsd	   relative	   to	   the	   lowest	  energy	  
structure.	   	  Each	  point	  is	  a	  plateau	  in	  the	  trajectory	  rmsd,	  representing	  a	  macrostate	  of	  
the	   system.	   	   The	   binding	   energy	   of	   the	   reference	   state	   calculated	   without	   including	  






Figure	   A.8.	   Structures	   of	   the	   E17K	   and	   WT	   reference	   states.	   	   There	   are	   distinct	  
differences	  in	  the	  conformation	  of	  the	  peptide	  around	  the	  E17K	  mutation	  cite	  between	  












	   This	  appendix	  explored	  the	  use	  of	  MD	  calculations	  to	  understand	  the	  selectivity	  
of	  the	  peptide	  ligand	  yleaf-­‐tosyl-­‐biotin	  for	  the	  E17K	  mutant	  of	  Akt1	  PH	  domain	  over	  the	  
wild	   type	   domain.	   	   The	   structure	   of	   the	   ligand	  was	   constructed	   and	  minimized,	   then	  
complexed	  with	  both	  the	  E17K	  and	  wild	  type	  structures	  of	  Akt1	  PHD.	  	  Trajectories	  were	  
run,	  and	  the	  energies	  of	  macrostates	  of	  the	  system	  were	  calculated	  and	  plotted	  against	  
their	  rmsd	  relative	  to	  a	  reference	  state	  to	  determine	  if	  the	  lowest	  energy	  state	  had	  been	  
identified.	   	   The	   binding	   energy	   of	   the	   E17K	   reference	   state	   was	   found	   to	   be	  
2.67	  kcal/mol	  lower	  than	  that	  of	  the	  WT	  reference	  state.	  	  This	  corresponds	  to	  a	  factor	  of	  
~90	  difference	  in	  Kd,	  which	  is	  within	  the	  error	  of	  experimental	  measurements.	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   Detecting	  the	  immune	  response	  to	  an	  infectious	  agent	  can	  provide	  useful	  in	  vitro	  
diagnostic	   information.	   	   Assays	   of	   this	   nature	   require	   a	   general	   antibody	   detection	  
agent,	   often	   a	   conjugated	   anti-­‐Fc	   antibody	   or	   protein	   substrate,	   i.e.,	   Protein	   A.	  	  
However,	   most	   biological	   reagents	   have	   inherent	   variability,	   which	   can	   adversely	  
influence	   the	   performance	   of	   the	   diagnostic	   test.	   	   Peptide	   capture	   agents	   have	   been	  
shown	  to	  be	  highly	  robust	  and	  inexpensive	  to	  produce,	  and	  to	  have	  similar	  affinities	  and	  
selectivities	   as	   antibodies.	   	   DeLano	   et	   al.	   reported	   the	   discovery	   of	   a	   cyclic	   13-­‐amino	  
acid	   peptide	   (Fc-­‐III)	   	   that	   bound	   the	   “consensus	   region”	   of	   IgG	   Fc	   by	   phage	   display	  
affinity	  screening	  [1].	  	  We	  explored	  possible	  improvements	  to	  the	  Fc-­‐III	  peptide	  in	  terms	  
of	  affinity	  and	  selectivity	  by	  employing	  in	  situ	  click	  screening	  to	  obtain	  a	  biligand,	  and	  in	  
terms	  of	   stability	  by	   replacing	   the	  disulfide	  bridge	  of	   Fc-­‐III,	  with	   the	   goal	   of	   using	   the	  
modified	  peptide	  as	  a	  detection	  agent	  in	  diagnostic	  assays.	  
	  
B.2	  WELLS	  PEPTIDE	  
	   Using	  a	  cyclic	  phage	  display	  library	  of	  the	  form	  XiCXjCXk	  (where	  C	  is	  cysteine,	  X	  is	  
a	  random	  amino	  acid,	  and	   i	  +	  j	  +	  k	  =	  18),	  Delano	  et	  al.	  found	  the	  13-­‐residue	  Fc	  binding	  
sequence	  Fc-­‐III	  (DCAWHLGELVWCT)	  [1,2].	  	  When	  synthesized,	  this	  peptide	  was	  found	  to	  
inhibit	   the	   binding	   of	   Protein	  A	   Z-­‐domain	   to	   Fc	  with	   a	  Ki	   of	   25	   nM,	  which	   is	   200	   fold	  
greater	   affinity	   than	   an	   earlier,	   longer	   consensus	   sequence	   found	   by	   the	   group.	   	   The	  
increased	   affinity	   with	   shorter	   length	   implied	   that	   the	   final	   sequence	   very	   efficiently	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interacts	  with	  the	  Fc	  binding	  pocket.	  	  We	  added	  a	  propargyl	  glycine	  (Pra)	  residue	  at	  the	  
N-­‐terminus	  of	  Fc-­‐III	  and	  tested	  the	  ability	  of	  this	  modified	  cyclic	  peptide	  to	  bind	  IgG	  Fc.	  	  
The	   anchor	   peptide,	   monikered	   Wells	   peptide,	   was	   also	   C-­‐terminally	   tagged	   with	   a	  
polyethylene	  glycol	  (PEG)	  oligomer	  bridge	  and	  a	  biotin	  label.	  	  	  
	  
B.3	  BILIGAND	  SCREEN	  
The	  in	  situ	  click	  screen	  is	  illustrated	  in	  Scheme	  2.1.	  	  The	  target	  IgG	  Fc	  is	  incubated	  
with	  an	  excess	  of	  the	  selected	  anchor	  peptide	  and	  a	  large	  OBOC	  library	  at	  4oC	  for	  6	  hrs	  
(see	  Materials	  and	  Methods).	  	  The	  OBOC	  library	  is	  synthesized	  on	  TentaGel	  resin	  (Rapp	  
Polymere,	   Tuebingen,	   Germany),	   and	   is	   a	   comprehensive	   library	   of	   5-­‐mers	  with	   a	   6th	  
amino	   acid	   at	   the	   C-­‐terminus	   presenting	   an	   azide	   functionality.	   	   The	   OBOC	   library	   is	  
comprised	   of	   non-­‐natural	   (D)	   stereoisomers	   of	   the	   natural	   amino	   acids,	   excluding	  
cysteine	   and	  methionine.	   	   The	   in	   situ	   screen	   is	   designed	   to	   identify	   a	   secondary	   (2o)	  
peptide	   that,	  when	   coupled	   to	   the	   anchor,	   forms	   a	   biligand	  with	   increased	   selectivity	  
and/or	  affinity	  for	  the	  target	  IgG	  Fc.	  	  	  
	   In	   Step	  1	  of	   the	   screen,	   the	  OBOC	   library	   is	   cleared	  of	  beads	   that	  exhibit	  non-­‐
specific	  binding	  to	  Wells	  peptide	  and	  alkaline	  phosphatase-­‐conjugated	  streptavidin	  (SA-­‐
AP),	  which	   is	  used	  as	  a	  detection	   reagent	   in	   the	  next	   step.	   	   Step	  2	   is	   called	  a	  product	  
screen,	   and	   is	   unique	   to	   sequential	   in	   situ	   click	   screens	   [3].	   	   This	   screen	   detects	   the	  
presence	  of	   in	  situ	  clicked	  reaction	  products,	  which	  are	  those	  hit	  beads	  containing	  the	  




Scheme	  B.1.	  Screening	  strategy	  for	  selecting	  capture	  agents	  against	  human	  IgG	  Fc.	  	  The	  
flow	  chart	  represents	  the	  use	  of	  the	  cyclic	  Wells	  peptide	  as	  an	  anchor	  ligand	  for	  in	  situ	  







Table	   B.1.	   Biligand	   screen	   results.	   	   List	   of	   pentapeptide	   “hits”	   from	   OBOC	   biligand	  
screens	   performed	   with	   Wells	   peptide	   and	   human	   IgG	   Fc.	   	   The	   selected	   secondary	  









B.4	  1,4	  TRIAZOLE	  LINKED	  BILIGAND	  CHARACTERIZATION	  
	   The	   performance	   of	   these	   biligands	   was	   then	   characterized	   using	   an	   in-­‐house	  
developed	  an	  on-­‐bead	  ELISA	  assay	   (data	  not	   shown).	   	   Sandwich	  ELISAs	  were	  used	   for	  
affinity	  estimations	  of	  the	  two	  best	  performing	  biligands	  (Figure	  B.1)	  from	  the	  on-­‐bead	  
experiments.	  	  The	  affinity	  increase	  of	  the	  biligands	  over	  Wells	  is	  marginal.	  	  Hill	  fits	  to	  the	  
ELISA	  data	  give	  Kd	  values	  of	  18	  nM	  for	  WA,	  21	  nM	  for	  WG,	  and	  25	  nM	  for	  Wells	  (Figure	  
B.2).	  
	   	   	   	  
B.5	  1,5	  TRIAZOLE	  LINKED	  BILIGAND	  CHARACTERIZATION	  
The	  in	  situ	  click	  process	  does	  not	  yield	  a	  stereospecific	  triazole	  product,	  and	  it	  is	  
impossible	   to	   measure	   which	   click	   product	   variant	   the	   protein	   “catalyzed”	   during	   a	  
screen.	   	   Therefore	   it	   can	  be	  useful	   to	   test	   the	  1,5	   triazole	   linked	  versions	  of	  potential	  
biligands.	   	   Here,	   the	   biligand	  WA	  was	   synthesized	   using	   a	   1,5	   triazole	   small	  molecule	  
linker	  and	  its	  performance	  compared	  to	  that	  of	  Wells	  by	  sandwich	  ELISA	  (Figures	  B.2	  -­‐	  










Figure	  B.1.	  Structures	  of	  peptide	  biligands	  identified	  in	  screen	  against	  IgG	  Fc.	  	  Acetylene-­‐
presenting	   anchor	   peptides	   (black)	   were	   derived	   from	   Fc-­‐III.	   	   Wells-­‐ahriG	   (WA)	   and	  
Wells-­‐Gehni	  (WG)	  were	  evolved	  from	  the	  original	  peptide	  appended	  with	  Pra	  at	  the	  N-­‐
terminus,	  and	  secondary	  ligand	  branches	  (colored)	  were	  identified	  from	  the	  in	  situ	  click	  












Figure	  B.2.	  Apparent	  affinity	  of	  Wells	  and	  biligands	  directed	  against	  Fc	  as	  determined	  by	  
sandwich	  ELISA.	  	  Lines	  represent	  1st	  order	  Hill	  fits	  to	  the	  affinity	  data.	  	  Wells:	  Kd	  =	  25	  nM,	  
















Figure	   B.3.	   Structure	   of	   1,5	   triazole	   linked	   biligand.	   	   Biligand	   peptide	   WA	   was	  














Figure	  B.4.	  Apparent	  affinity	  of	  Wells	  and	  1,5	  triazole	  linked	  WA	  directed	  against	  Fc	  as	  















B.6	  CLICK	  CYCLIZED	  WELLS	  	  
To	  enhance	  the	  stability	  of	   the	  Wells	  anchor	  peptide,	  we	  attempted	  to	  replace	  
the	  disulphide	  bridge	  with	  a	  Cu(I)	  catalyzed	  click	  triazole.	   	   (D)	  or	  (L)	  azidoalanine	  (Az1)	  
was	   substituted	   for	   Cys2,	   and	   Pra	   was	   substituted	   for	   Cys12,	   then	   the	   peptide	   was	  
cyclized	  using	  Cu(I)	   catalyzed	   click	   chemistry	   (Figure	  B.5).	   	   Single	  point	   ELISAs	   showed	  
that	  this	  approach	  to	  cyclization	  removed	  all	  affinity	  to	  IgG	  Fc	  (Figure	  B.6).	  	  This	  could	  be	  
due	   to	   the	   change	   in	   confirmation	   of	   the	   peptide	   cycle	   when	   constrained	   by	   an	  
alternative	   cyclization	   moiety.	   	   The	   use	   of	   both	   (D)	   and	   (L)	   Az1	   was	   an	   attempt	   to	  










Figure	  B.5.	   Structure	  of	  Cu(I)	   click	  cyclized	  Wells	  peptide.	   	  The	  disulfide	  bond	   in	  Wells	  
peptide	  was	   replaced	  with	  a	  Cu(I)	   catalyzed	   triazole	   formed	   from	  substitutions	  of	  Az1	  







Figure	   B.6.	   Performance	   of	   click	   cylized	   Wells	   peptide	   variants	   compared	   to	   Wells	  
peptide	   tested	   by	   sandwich	   ELISA.	   	   Fc	   (500	   nM)	   was	   spiked	   into	   TBS,	   and	   captured	  











B.7	  MATERIALS	  AND	  METHODS	  
B.7.1	  Anchor	  Synthesis	  
	   The	   anchor	   Wells	   peptide	   was	   synthesized	   C	  →	  N	   on	   200-­‐300	   mgs	   of	   Biotin	  
NovaTag	  resin	  (EMD	  Biosciences,	  San	  Diego,	  CA)	  with	  a	  Titan	  peptide	  synthesizer	  using	  
standard	   Fmoc	   chemistry	   [4].	   	   The	   synthesis	   used	   Fmoc	   and	   side	   chain	   protected	   L	  
amino	   acids	   (Aaptec,	   Louisville,	   KY),	   Fmoc	   protected	   propargylglycine	   (Pra)	   (Aaptec,	  
Louisville,	  KY)	  and	  PEG5	  (EMD	  Millipore,	  Germany).	  	  The	  finished	  peptide	  was	  side-­‐chain	  
deprotected	  and	   cleaved	   from	   resin	   in	   a	  mixture	  of	   95%	  v/v	   trifluoroacetic	   acid	   (TFA)	  
(Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  5%	  v/v	  dH2O,	  and	  5%	  triethylsilane	  (TES)	  (Sigma-­‐Aldrich,	  
St.	  Louis,	  MO),	  and	  precipitated	  in	  diethyl	  either.	  	  Cu(Phen)3	  stock	  solution	  was	  prepared	  
by	  mixing	   150	  mM	  Cu(II)	   sulfate	   pentahydrate	   (Sigma-­‐Aldrich,	   St.	   Louis,	  MO)	   and	   500	  
mM	  1,10-­‐phenanthroline	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO)	  in	   	  4:1	  H2O:Ethanol.	  The	  ether-­‐
precipitated	   ligand	   was	   cyclized	   by	   stirring	   the	   cleaved	   peptides	   dissolved	   in	   ~5	   mL	  
acetonitrile	   (ACN)	  overnight	  with	  1	  mL	  of	  the	  Cu(Phen)3	  stock	  solution.	  The	  cyclization	  
mixture	  was	  lyophilized,	  and	  the	  final	  peptide	  product	  was	  purified	  using	  reverse	  phase	  
(RP)	  HPLC	  on	  a	  Kinetex	  5µ	  XB-­‐C18	  250	  x	  4.6	  mm	  prep	  column	  (Phenomenex,	  Torrance,	  
CA).	  	  
	  
B.7.2	  OBOC	  Screen	  
	   The	   screen	   used	   naïve	   one-­‐bead-­‐one-­‐compound	   (OBOC)	   D-­‐pentapeptide	  
libraries	  on	  TentaGel	  resin	  (TG)	  (Rapp	  Polymere,	  Tuebingen,	  Germany)	  of	  the	  form	  NH2-­‐
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X1X2X3X4X5-­‐Az4-­‐TG,	   excluding	   cysteine	   and	   methionine,	   where	   Az4	   is	   L-­‐azidolycine.	  	  
Libraries	  were	  synthesized	  on	  a	  Titan	  peptide	  synthesizer	  (Aaptec,	  Louisville,	  KY)	  using	  a	  
split/mix	  method,	  and	  couplings	  were	  done	  using	  standard	  Fmoc	  SPPS	  chemistry	   in	  N-­‐
methylpyrrolidone	  (NMP).	  	  	  
	   Screening	  against	  Fc	  was	  carried	  out	   in	   two	  main	  steps:	  pre-­‐clear,	  and	  product	  
screen.	  	  Step	  1	  preclear:	  200	  mg	  of	  OBOC	  library	  was	  blocked	  in	  5%	  w/v	  dry	  milk	  in	  Tris	  
buffered	  saline	  (TBS)	  (25	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  10	  mM	  MgCl2,	  pH	  7.6)	  for	  2	  hr	  at	  
room	   temperature,	   and	   then	   incubated	   with	   1:10,000	   phosphatase-­‐conjugated	  
streptavidin	  (SA-­‐AP,	  Promega,	  Madison,	  WI)	  and	  25	  µM	  Wells	  peptide	   in	  0.5%	  w/v	  dry	  
milk	   in	  TBS	  for	  1	  hr.	   	  The	  beads	  were	  washed	   in	  high	  salt	  buffer	   (25	  mM	  Tris-­‐HCl,	  750	  
mM	  NaCl,	  10	  mM	  MgCl2,	  pH	  7.6)	  for	  1	  hr,	  and	  then	  developed	  with	  BCIP/NBT	  (Promega,	  
Madison,	  WI)	  in	  BCIP	  buffer	  (100	  mM	  Tris-­‐HCl,	  150	  mM	  NaCl,	  1	  mM	  MgCl2,	  pH	  9).	  	  	  After	  
1	   hour,	   the	   reaction	   was	   quenched	   with	   conc.	   HCl,	   and	   the	   purple	   beads	   were	  
discarded.	  	  The	  remaining	  library	  was	  decolorized	  in	  NMP,	  dried	  with	  methanol	  (MeOH)	  
and	  dichloromethane	  (DCM),	  and	  then	  swelled	  and	  blocked	  in	  5%	  w/v	  dry	  milk	  in	  TBS	  for	  
2	  hr	  at	  room	  temperature.	  	  Step	  2	  product	  screen:	  4	  mL	  of	  a	  solution	  containing	  25	  µM	  
A21	   and	   23	   nM	   Fc	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   was	   added	   to	   the	   precleared	   OBOC	  
library,	  and	  the	   in	   situ	   click	   reaction	  was	  allowed	  to	  proceed	   for	  6	  hours	  at	  4°C.	   	  Click	  
solution	  was	  drained	  and	  the	  beads	  were	  washed	  for	  1	  hr	  in	  high	  salt	  buffer.	  	  The	  beads	  
were	  incubated	  for	  1	  hr	  at	  room	  temperature	  with	  1:10,000	  SA-­‐AP	  in	  0.5%	  w/v	  dry	  milk	  
in	  TBS,	  washed	  for	  1	  hr	  with	  high	  salt	  buffer,	  and	  then	  developed	  with	  BCIP/NBT	  in	  BCIP	  
buffer	   for	   1	   hour.	   	   The	   reaction	  was	   quenched	  with	   conc.	   HCl,	   and	   the	   purple	   beads	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were	   retained	   and	   sequenced	   using	   a	   Procise	   CLC	   Edman	   Degradation	   Protein	  
Sequencing	  System	  (Applied	  Biosystems,	  Kingston,	  RI).	  	  	  
	  
B.7.3	  Biligand	  Synthesis	  
1,4	  Triazole	  linked	  WA	  and	  WG	  
	   The	  secondary	  ligands	  including	  C-­‐terminal	  Az4	  for	  WA	  and	  WG	  were	  synthesized	  
C	  →	  N	   on	   200-­‐300	   mgs	   of	   Rink	   amide	   resin	   with	   a	   Titan	   peptide	   synthesizer	   using	  
standard	  Fmoc	  chemistry.	   	  The	  synthesis	  used	  Fmoc	  and	  side	  chain	  protected	  D	  amino	  
acids	   and	   L-­‐Az4	   (Aaptec,	   Louisville,	   KY).	   	   The	   ligands	  were	   side-­‐chain	   deprotected	   and	  
cleaved	   from	   resin	   in	   95:5:5	   TFA:dH2O:TES,	   then	   precipitated	   in	   diethyl	   either	   and	  
purified	  using	  RP-­‐HPLC	  on	  a	  Kinetex	  5µ	  XB-­‐C18	  250	  x	  4.6	  mm	  prep	  column.	  	  The	  purified	  
secondary	   ligands	   were	   clicked	   to	   cyclized	   Wells	   peptide	   in	   solution	   using	   2x	   molar	  
excess	  of	  secondary,	  10x	  Cu(I)	  iodide,	  50x	  L-­‐ascorbic	  acid,	  and	  4x	  Tris[(1-­‐benzyl-­‐1H-­‐1,2,3-­‐
triazol-­‐4-­‐yl)methyl]amine	   (TBTA)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   in	   5:1	   NMP:dH2O	   and	  
stirring	   overnight	   at	   room	   temperature.	   	   The	   clicked	   biligand	   products	   were	   purified	  
from	  the	  reaction	  mixture	  by	  RP-­‐HPLC	  on	  a	  C18	  semi	  prep	  column.	  	  
	  
1,5	  Triazole	  linked	  WA	  
	   	  The	   anchor	   peptide	   was	   synthesized	   C	  →	  N	   omitting	   Pra	   on	   200-­‐300	   mgs	   of	  
Biotin	  NovaTag	  resin	  (EMD	  Biosciences,	  San	  Diego,	  CA)	  with	  a	  Titan	  peptide	  synthesizer	  
using	  standard	  Fmoc	  chemistry	   [4].	   	  A	  pre-­‐clicked	  Fmoc	  protected	  1,5	   triazole	  Pra-­‐Az4	  
small	  molecule	  linker	  (InDi	  Molecular)	  was	  amide	  coupled	  to	  the	  N-­‐terminal	  Asp	  of	  Wells	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peptide,	  which	  after	  Fmoc	  deprotection	  served	  as	  the	  starting	  point	  for	  the	  synthesis	  of	  
the	   secondary	   ligand.	   	   The	   finished	   peptide	   was	   side-­‐chain	   deprotected	   and	   cleaved	  
from	   resin	   in	   a	  mixture	   of	   95%	   v/v	   trifluoroacetic	   acid	   (TFA)	   (Sigma-­‐Aldrich,	   St.	   Louis,	  
MO),	   5%	   v/v	   dH2O,	   and	   5%	   triethylsilane	   (TES)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO),	   and	  
precipitated	  in	  diethyl	  either.	  	  Cu(Phen)3	  stock	  solution	  was	  prepared	  by	  mixing	  150	  mM	  
Cu(II)	   sulfate	   pentahydrate	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   and	   500	   mM	   1,10-­‐
phenanthroline	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   in	   	  4:1	   H2O:Ethanol.	   The	   ether-­‐
precipitated	   ligand	   was	   cyclized	   by	   stirring	   the	   cleaved	   peptides	   dissolved	   in	   ~5	   mL	  
acetonitrile	   (ACN)	  overnight	  with	  1	  mL	  of	  the	  Cu(Phen)3	  stock	  solution.	  The	  cyclization	  
mixtures	   were	   lyophilized,	   and	   the	   final	   peptide	   product	   was	   purified	   using	   reverse	  
phase	  (RP)	  HPLC	  on	  a	  C18	  prep	  column	  (Phenomenex,	  Torrance,	  CA).	  
	  
B.7.4	  Click	  Cyclized	  Wells	  Synthesis	  
	   The	  anchor	  Wells	  peptide	  was	  synthesized	  C	  →	  N,	  including	  N-­‐terminal	  PEG	  and	  
biotin,	  on	  200-­‐300	  mgs	  of	  Rink	  amid	  resin	  (AnaSpec,	  Fremont,	  CA)	  with	  a	  Titan	  peptide	  
synthesizer	  using	  standard	  Fmoc	  chemistry	  [4].	  	  The	  synthesis	  used	  Fmoc	  and	  side	  chain	  
protected	  L	  amino	  acids	  (Aaptec,	  Louisville,	  KY),	  Fmoc	  protected	  propargylglycine	  (Pra)	  
(Aaptec,	  Louisville,	  KY),	  Fmoc	  protected	  (D)	  and	  (L)	  azidoalanine	  (Iris	  Biotech,	  Germany),	  
PEG5	  (EMD	  Millipore,	  Germany),	  and	  biotin	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO).	  	  The	  finished	  
peptide	   was	   side-­‐chain	   deprotected	   and	   cleaved	   from	   resin	   in	   a	   mixture	   of	   95%	   v/v	  
trifluoroacetic	   acid	   (TFA)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO),	   5%	   v/v	   dH2O,	   and	   5%	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triethylsilane	  (TES)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  and	  precipitated	  in	  diethyl	  either.	   	  A	  
Cu(I)	   click	   cyclization	   solution	  was	  prepared	  by	  mixing	  10x	  Cu(I)	   iodide,	  50x	   L-­‐ascorbic	  
acid,	  and	  4x	  Tris[(1-­‐benzyl-­‐1H-­‐1,2,3-­‐triazol-­‐4-­‐yl)methyl]amine	  (TBTA)	  (Sigma-­‐Aldrich,	  St.	  
Louis,	  MO)	  in	  5:1	  NMP:dH2O.	  The	  ether-­‐precipitated	  ligands	  were	  cyclized	  by	  stirring	  the	  
cleaved	  peptides	  dissolved	   in	  ~2	  mL	  Cu(I)	   click	  solution.	   	  The	  clicked	  biligand	  products	  
were	  purified	  from	  the	  reaction	  mixture	  by	  RP-­‐HPLC	  on	  a	  C18	  semi	  prep	  column.	  	  
	  
B.7.5	  Assays	  
Biligand	  binding	  ELISA	  
	   Biotinylated	   WA,	   WG,	   and	   Wells	   peptides	   were	   immobilized	   on	   streptavidin-­‐
coated	  96-­‐well	  plates	  (Thermo	  Scientific	  Pierce,	  Rockford,	  IL)	  at	  a	  concentration	  of	  400	  
nM	  in	  TBS.	  	  The	  plates	  were	  blocked	  with	  5%	  w/v	  dry	  milk	  in	  TBS,	  and	  then	  the	  anchor	  
peptides	  were	  incubated	  with	  varying	  concentrations	  of	  Fc	  in	  0.5%	  w/v	  dry	  milk	  in	  TBS	  at	  
room	  temperature	   for	  1	  hr.	   	  Bound	  antibody	  was	  probed	  with	  horseradish	  peroxidase	  
(HRP)-­‐conjugated	   mouse	   monoclonal	   antibody	   to	   human	   IgG	   Fc	   (Abcam,	   Cambridge,	  
MA),	  diluted	  1:10,000	   in	  0.5%	  w/v	  dry	  milk	   in	  TBS	  for	  1	  hr	  at	   room	  temperature.	   	  The	  
colorimetric	   assay	   was	   developed	   with	   TMB	   substrate	   (KPL,	   Gaithersburg,	   MD),	   then	  
quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm.	  	  
	  
1,5	  triazole	  linked	  biligand	  binding	  ELISA	  
	   Biotinylated	   1,5	   triazole	   linked	   WA	   peptide	   was	   immobilized	   on	   streptavidin-­‐
coated	  96-­‐well	  plates	  (Thermo	  Scientific	  Pierce,	  Rockford,	  IL)	  at	  a	  concentration	  of	  300	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nM	  in	  TBS.	  	  The	  plates	  were	  blocked	  with	  5%	  w/v	  dry	  milk	  in	  TBS,	  and	  then	  the	  anchor	  
peptides	  were	  incubated	  with	  varying	  concentrations	  of	  Fc	  in	  0.5%	  w/v	  dry	  milk	  in	  TBS	  at	  
room	  temperature	   for	  1	  hr.	   	  Bound	  antibody	  was	  probed	  with	  horseradish	  peroxidase	  
(HRP)-­‐conjugated	   mouse	   monoclonal	   antibody	   to	   human	   IgG	   Fc	   (Abcam,	   Cambridge,	  
MA),	  diluted	  1:10,000	   in	  0.5%	  w/v	  dry	  milk	   in	  TBS	  for	  1	  hr	  at	   room	  temperature.	   	  The	  
colorimetric	   assay	   was	   developed	   with	   TMB	   substrate	   (KPL,	   Gaithersburg,	   MD),	   then	  
quenched	  with	  1	  M	  H2SO4	  and	  read	  at	  450	  nm.	  	  
	  
Click	  cyclized	  Wells	  ELISA	  
	   Biotinylated	  Cu(I)	   click	   cyclized	  Wells	  peptide	  was	   immobilized	  on	   streptavidin-­‐
coated	  96-­‐well	  plates	  (Thermo	  Scientific	  Pierce,	  Rockford,	  IL)	  at	  a	  concentration	  of	  1	  µM	  
in	   TBS.	   	   The	   plates	   were	   blocked	  with	   5%	  w/v	   dry	  milk	   in	   TBS,	   and	   then	   the	   anchor	  
peptides	   were	   incubated	   with	   500	   nM	   of	   Fc	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   at	   room	  
temperature	  for	  1	  hr.	  	  Bound	  antibody	  was	  probed	  with	  horseradish	  peroxidase	  (HRP)-­‐
conjugated	   mouse	   monoclonal	   antibody	   to	   human	   IgG	   Fc	   (Abcam,	   Cambridge,	   MA),	  
diluted	   1:10,000	   in	   0.5%	   w/v	   dry	   milk	   in	   TBS	   for	   1	   hr	   at	   room	   temperature.	   	   The	  
colorimetric	   assay	   was	   developed	   with	   TMB	   substrate	   (KPL,	   Gaithersburg,	   MD),	   then	  







	   Described	  in	  this	  appendix	  is	  an	  attempt	  to	  improve	  the	  previously	  discovered	  Fc	  
binding	  peptide	  Fc-­‐III	   in	   terms	  of	  affinity,	   selectivity,	  and	  stability.	   	  While	  a	  number	  of	  
approaches	  were	  taken,	  the	  performance	  of	  the	  original	  Wells	  anchor	  peptide	  was	  not	  
significantly	   improved.	   	   Preliminary	   immunoprecipitation	   data	   (not	   shown)	   indicated	  
possible	   selectivity	   enhancement,	   but	   was	   not	   verified.	   	   The	   lack	   of	   improvement	   of	  
Wells	  peptide	  with	   the	  addition	  of	  a	   secondary	   ligand	  may	  reflect	   the	   increased	  dwell	  
time	   that	   such	   a	   strong	   binder	   has	   with	   its	   target	   during	   a	   screen;	   there	   are	   less	  
significant	  constraints	  on	  the	  nature	  of	  the	  secondary	  ligand	  that	  clicks	  to	  the	  anchor	  in	  
the	   in	  situ	  process	  due	  to	   the	  relatively	  constant	  presence	  of	   the	  anchor	   ligand	  at	   the	  
target	  binding	  site.	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   The	   one-­‐bead-­‐one-­‐compound	   in	   situ	   click	   screening	   approach	   often	   yields	   a	  
number	   of	   peptide	   “hits.”	   	   Rather	   than	   synthesizing	   and	   vetting	   each	   individual	  
sequence,	   it	   can	   be	   useful	   to	   group	   the	   results	   into	   clusters	   of	   peptides	   based	   on	  
physical	  properties,	  and	   then	   to	  choose	  a	   representative	  peptide	   from	  each	  cluster	   to	  
scale	  up	  and	  test.	  	  This	  appendix	  provides	  an	  example	  clustering	  algorithm	  that	  uses	  the	  
concept	  of	  persistence	  homology	  to	  group	  peptides	  by	  hydrophobicity,	  isoelectric	  point,	  
and	  residue	  weight.	  	  The	  grouping	  is	  amino	  acid	  order	  dependent.	  
	  
C.2	  PERSISTENCE	  CLUSTERING	  
	   Persistence	  states	  that	  structures	  that	  persist	  at	  multiple	  scales	  are	  most	  likely	  to	  
be	   real.	   	   For	   example,	   if	   an	   image	   is	   sampled	   by	   using	   a	   small	   number	   of	   points,	  
persistence	  can	  be	  used	  to	  determine	  properties	  of	  the	  original	  shape.	   	  The	  points	  are	  
grouped	  by	  drawing	  a	  disc	  of	  radius	  ε	  around	  each	  point.	  	  Each	  collection	  of	  overlapping	  
discs	   is	  considered	  a	  cluster.	   	  These	  clusters	  provide	  one	  possible	  interpretation	  of	  the	  
original	  data.	  
To	  obtain	  a	  more	  complete	  analysis	  of	  the	  data,	  ε	  is	  continuously	  varied	  and	  the	  
clusters	  tracked	  as	  the	  discs	  grow	  around	  the	  points.	  	  As	  discs	  from	  one	  cluster	  begin	  to	  
overlap	  with	  discs	  from	  another	  cluster,	  the	  two	  initial	  clusters	  “die”	  and	  a	  new	  merged	  
cluster	   is	   “born.”	   	   The	   lifetime	   of	   a	   cluster	   is	   the	   time	   between	   a	   cluster’s	   birth	   and	  
death.	   	  Thus,	  groups	  of	  points	   that	  are	   far	   from	  other	  points	  will	  have	  a	   long	   lifetime,	  




Figure	   C.1.	   	   Discs	   formed	   around	   points	   with	   growing	   radius	   ε.	   	   As	   the	   discs	   around	  
points	  overlap,	  new	  clusters	  form	  that	  include	  points	  rooting	  the	  newly	  touching	  discs.	  
Eventually	  all	  the	  discs	  will	  touch,	  and	  the	  cluster	  containing	  all	  points	  will	  continue	  for	  

















C.3	  ALGORITHM	  DESCRIPTION	  
	   The	  MatLab	   function	  BasicParam	   takes	   as	   input	   text	   files	   that	   contain	   a	   list	   of	  
sequences	  and	  the	  number	  n	  of	  amino	  acids	  per	  sequence.	  	  It	  then	  uses	  hydrophobicity,	  
isoelectric	   point,	   and	   residue	  weight	   to	   construct	   a	   point	   in	   3n	   dimensional	   for	   each	  
sequence.	   	  To	  prevent	  any	  of	   the	  physical	  parameters	   from	  overly	  contributing	   to	   the	  
clustering	  based	  on	  their	  absolute	  amounts,	   they	  are	  all	   scaled	  by	   the	   inverse	  of	   their	  
average.	   	   Once	   each	   sequence	   is	   represented	   by	   a	   point,	   the	   Euclidian	   pair	   wise	  
distances	   between	   the	   points	   are	   computed.	   	   Initially,	   each	   point	   is	   its	   own	   cluster.	  	  
Then,	  the	  two	  points	  with	  the	  smallest	  pair	  wise	  distance	  are	  merged.	  	  The	  time	  of	  death	  
of	  the	  initial	  point	  clusters,	  and	  the	  time	  of	  birth	  of	  the	  new	  merged	  cluster,	  is	  set	  to	  the	  
distance	  between	  those	  two	  points	  (see	  Figure	  B.2).	  	  Clusters	  containing	  points	  with	  the	  
next	  least	  distance	  continue	  to	  iteratively	  merge	  until	  all	  points	  in	  the	  data	  set	  exist	  as	  a	  
single	   cluster.	   	   Additionally,	   a	   covariance	  matrix	  was	   constructed	   and	   diagonalized	   to	  
find	  the	  eigenvectors	  and	  eigenvalues	  that	  characterize	  the	  sequence	  space.	  
	  
C.4	  OUTPUT	  
	   The	  function	  outputs	  a	  list	  of	  clusters	  and	  their	  associated	  lifetimes,	  along	  with	  a	  
plot	  of	  the	  input	  sequences	  projected	  onto	  the	  top	  two	  eigenvectors.	  	  The	  complete	  list	  
of	   eigenvectors	   is	   also	   plotted	   against	   the	   associated	   eigenvalues,	   and	   the	   top	   four	  
eigenvectors	  are	  decomposed	   into	   their	   individual	   components	  as	   charts.	   	   The	  output	  
from	  clustering	  the	  hits	  obtained	  in	  the	  A22/4B3	  screen	  described	  in	  Chapter	  2	  is	  shown	  





Figure	  C.2.	  	  Illustrative	  example	  of	  how	  lifetimes	  of	  clusters	  are	  computed.	  	  The	  lifetimes	  
of	  clusters	  “a”	  and	  “b”	  are	  3,	  because	  they	  are	  closer	  to	  each	  other	  than	  any	  other	  point	  
and	  that	  is	  the	  distance	  between	  them.	  	  3	  then	  becomes	  the	  birth	  time	  for	  cluster	  “ab,”	  





Table	  C.1.	  	  List	  of	  clusters	  and	  their	  associated	  lifetimes	  calculated	  for	  the	  hits	  resulting	  
from	  the	  A22/4B3	  screen.	  	  The	  peptides	  input	  to	  the	  algorithm	  were	  qndwk,	  ltsry,	  diksp,	  













Figure	  C.3.	  Projection	  of	  the	  peptide	  “points”	  onto	  the	  top	  two	  eigenvectors	  taken	  from	  
the	   diagonalization	   of	   the	   covariance	  matrix.	   	   The	   clusters	   containing	  more	   than	   one	  





Figure	  C.4.	   	  Plot	  of	  eigenvectors	  vs.	   their	  associated	  eigenvalues.	   	  This	  allows	  users	   to	  







Figure	  C.5.	  	  Visual	  representation	  of	  the	  components	  of	  the	  top	  four	  eigenvectors.	  	  This	  
shows	   what	   physical	   characteristics	   are	   dominant	   when	   describing	   the	   list	   of	   input	  
peptides.	   	   The	   order	   of	   the	   amino	   acids	   is	   preserved	   during	   clustering,	   so	  
Hydrophobicity1	   refers	   to	   the	   hydrophobicity	   of	   the	   N-­‐terminal	   amino	   acid	   of	   the	  
peptides.	  	  For	  this	  set,	  the	  top	  four	  eigenvectors	  have	  large	  hydrophobicity	  components,	  
though	  not	  all	  from	  the	  same	  amino	  acid	  index.	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C.5	  FUNCTION	  CODE	  
function BasicParam(filename, pepLength) 
  
%Feb 8, 2013 
%Physical parameters come from the wwHydrophobicity scale, Sigma PI 
values, 
%and resudue weight. 
%Note: hydrophobicities are at pH 7 except for proline, which was 
estimated 
%from an InDi (or AN SD) measurement 
%Note: the number of traits is hard coded in, so that has to be changed 















scaling = [Hydr PI RW]; 
%scaling = 1; 
  
%[Hydrophobicity pI ResidueWeight] 
  
A = [41 6.00 71.08].*scaling; 
C = [49 5.07 103.15].*scaling; 
D = [-55 2.77 115.09].*scaling; 
E = [-31 3.22 129.12].*scaling; 
F = [100 5.48 147.18].*scaling; 
G = [0 5.97 57.05].*scaling; 
H = [8 7.59 137.14].*scaling; 
I = [99 6.02 113.16].*scaling; 
K = [-23 9.74 128.18].*scaling; 
L = [97 5.98 113.16].*scaling; 
M = [74 5.74 131.20].*scaling; 
N = [-28 5.41 114.11].*scaling; 
P = [50 6.30 97.12].*scaling; 
Q = [-10 5.56 128.13].*scaling; 
R = [-14 10.76 156.19].*scaling; 
S = [-5 5.68 87.07].*scaling; 
T = [13 5.60 101.11].*scaling; 
V = [76 5.96 99.13].*scaling; 
W = [97 5.89 186.22].*scaling; 
Y = [63 5.66 163.18].*scaling; 
  




sequences = textread(filename,'%s', -1); 
nseq = length(sequences); 
  
%Initialize matrix to hold each sequence vector 
ntrait = 3; 
Z=zeros(nseq,pepLength*ntrait); 
  
%For each individual sequence assign a vector based on Grantham Values  
for j = 1:nseq 
    seq = sequences{j}; 
    o = []; 
     
    for i=1:length(seq) 
     
    switch seq(i) 
        case 's' 
            o = [o S]; 
        case 'r' 
            o = [o R]; 
        case 'l' 
            o = [o L]; 
        case 'p' 
            o = [o P]; 
        case 't' 
            o = [o T]; 
        case 'a' 
            o = [o A]; 
        case 'v' 
            o = [o V]; 
        case 'g' 
            o = [o G]; 
        case 'i' 
            o = [o I]; 
        case 'f' 
            o = [o F]; 
        case 'y' 
            o = [o Y]; 
        case 'c' 
            o = [o C]; 
        case 'h' 
            o = [o H]; 
        case 'q' 
            o = [o Q]; 
        case 'n' 
            o = [o N]; 
        case 'k' 
            o = [o K]; 
        case 'd' 
            o = [o D]; 
        case 'e' 
            o = [o E]; 
        case 'm' 
            o = [o M]; 
        case 'w' 
            o = [o W]; 
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    end 
  
    end 
  Z(j,:) = o; 
end 
  
%Compute pairwise distances between each "sequence point" given by  
%a row in the Z matrix and put in array n.  Also, create a 2x#pairs 
matrix 




for i = 1:nseq 
    for j = i+1:nseq 
        n(k) = norm(Z(i,:)-Z(j,:)); 
        Idx(1,k) = i; 
        Idx(2,k) = j; 
        k=k+1; 
    end 
end 
  
%Sort the array of distances from smallest to largest and use returned 
%permutation to analogously sort pair indices. 
[N,O] = sort(n); 
Idx = Idx(:,O); 
  
%Create array of parents of "sequence points" 
p = [1:nseq]; 
  
%Create an array of cluster birth  
tb = zeros(1,nseq); 
  
% %Union the points with distance smaller than 200 
% for k = 1:length(N) 
%     if(N(k)>= 200) 
%         %sprintf('stopping at distance %f\n', N(k)) 
%         break; 
%     end 
%   %sprintf('Unioning %f and %f with distance 
%f\n',Idx(1,k),Idx(2,k),N(k)) 
%   p = Union(Idx(1,k),Idx(2,k),p); 
% end 
  
% %'Find' all points to see which ones share a root after Union and put 
into  
% %array 'root' 
% for i = 1:nseq 
%     j = Find(i,p); 
%     root(i) = j; 
% end 
  





%Itteratively 'Union' clusters containing the points with the next  
%least distance 
  
sets = {}; 
ages = []; 
birth = []; 
death = []; 
for i = 1:length(N) 
     
    %Find roots of the two sets being joined 
    r1 = Find(Idx(1,i),p); 
    r2 = Find(Idx(2,i),p);     
     
    %Set the current time to the distance between the two merging 
clusters 
    t = N(i); 
     
    %Check if the two sequences are already in the same cluster 
    if r1 ~= r2 
     
    %Save the sequences in the two merging clusters  
    %disp('====================================='); 
    set1 = MkSet(r1,nseq,p,sequences); 
    set2 = MkSet(r2,nseq,p,sequences); 
    
    sets(end+1) = {set1}; 
    sets(end+1) = {set2}; 
     
    %Compute and save the ages of the merging clusters 
    age1 = t - tb(r1); 
    age2 = t - tb(r2);     
     
    ages = [ages age1]; 
    ages = [ages age2]; 
     
    %Keep running tally of birth/death times for persistence barcode 
    birth = [birth tb(r1)]; 
    birth = [birth tb(r2)]; 
         
    death = [birth t]; 
    death = [birth t]; 
     
    %Union the two clusters 
    p = Union(Idx(1,i),Idx(2,i),p); 
     
    %Save birth time for new cluster 
    tb(r2) = t; 
     








[Ages,O_A] = sort(ages, 'descend'); 
Sets = sets(O_A); 
  
%Read out vectors of ages and sets 
 %disp('--------------------------------------------------------') 
 %DispSet(sets, ages); 
% disp('--------------------------------------------------------') 
 DispSet(Sets, Ages); 
 disp('--------------------------------------------------------') 
  





%Do PCA analysis to see if there exist any major axes along which the 
%sequence data falls. 
  
m = size(Z); 
  
%Center data 
center = zeros(1,m(2)); 
for i = 1:nseq 
center = center + Z(i,:); 
end 
center = center/nseq; 
Zc = zeros(m); 
for i = 1:nseq 
Zc(i,:) = Z(i,:) - center; 
end 
  
%Create covarience matrix 
covar = zeros(m(2), m(2)); 
CoVar = zeros(m(2), m(2)); 
for i = 1:nseq 
    covar = Zc(i,:)'*Zc(i,:); 
    CoVar = CoVar + covar; 
end 
  
%Diagonalize covarience matrix to find largest eigenvalues and 
%corresponding eigenvectors 
[vec,val] = eig(CoVar); 
CoVar*vec - vec*val; 
  
%Plot eigenvalues and display eigenvectors associated with two largest 
%values.  Also label eigenvectors with next two largest eigenvalues to 
%decompose into pie charts to examine components. 
Diagval = diag(val); 
[Val,O_val] = sort(Diagval, 'descend'); 
Vec = vec(:,O_val); 
plot(Val, '.k', 'MarkerSize',10); 
eig1 = Vec(:,1); eig2 = Vec(:,2); eig3 = Vec(:,3); eig4 = Vec(:,4); 
  
%Project sequence points onto the two largest eigenvectors and plot 




%Create pie chart to examine the components of the four eigenvectors 
with 
%the largest eigenvalues 
labels = {'Hydrophobicity_1', 'pI_1', 'RW_1','Hydrophobicity_2', 
'pI_2',... 
    'RW_2', 'Hydrophobicity_3', 'pI_3', 'RW_3', 'Hydrophobicity_4', 
'pI_4',... 























function y = Find(x,p) 
    y = x; 
    while(p(y)~=y) 
        y = p(y); 
    end 
end 
  
function p = Union(x1,x2,p) 
    r1 = Find(x1,p); 
    r2 = Find(x2,p); 
    p(r1) = r2; 
end 
  
function Set = MkSet(r1,nseq,p,seq) 
    Set = {}; 
    for i = 1:nseq 
        r = Find(i,p); 
        if r == r1 
            Set(end+1) = seq(i); 
        end 
    end 
end 
             
function DispSet(Sets, Ages) 
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    for i = 1:length(Sets) 
        Si = Sets{i}; 
        str = sprintf('%f\t',Ages(i)); 
        for j=1:length(Si) 
            str = sprintf('%s %s\t', str, char(Si{j})); 
        end 
        disp(str); 
    end 
end 
  
function Projection(eig1, eig2, Zc, sequences, nseq) 
x = []; 
y = []; 
    for i = 1:nseq 
        x = [x Zc(i,:)*eig1]; 
        y = [y Zc(i,:)*eig2]; 
    end 
    figure; 
    plot(x, y, '*') 
    dx = .2; dy = 0.2; 
    text(x+dx, y+dy, sequences); 
end 




	   This	   appendix	   describes	   a	   clustering	   algorithm	   designed	   to	   help	   characterize	  
groups	  of	  peptide	  hits	   from	   in	   situ	   click	   screens.	   	  The	  objective	   is	   to	  provide	  guidance	  
about	  which	  peptides	  are	  useful	  to	  scale	  up	  and	  assay,	  and	  give	  information	  about	  the	  
physical	   characteristics	   that	   predominately	   describe	   the	   differences	   between	   input	  
peptides.	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Appendix	  D	  
A	  cocktail	  of	  thermally	  stable,	  chemically	  synthesized	  capture	  agents	  for	  the	  efficient	  






























	   	  
	  
Appendix	  E	  
A	  Selective	  15N-­‐to-­‐1H	  Polarization	  Transfer	  Sequence	  for	  More	  Sensitive	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